| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.954 | 0.002 | 0.954 | Dopamine D4 antagonist | 0.773 0.003 DBMET02462 0.769 0.003 DBMET02463 0.89 0.003 DBMET02464 0.794 0.003 DBMET01611 0.758 0.003 DBMET01612 0.288 0.008 DBMET01613 0.453 0.004 DBMET02465 0.691 0.003 DBMET02456 0.655 0.004 DBMET02458 | ||
| 0.896 | 0.003 | 0.897 | Dopamine D2 antagonist | 0.801 0.003 DBMET02462 0.795 0.003 DBMET02463 0.897 0.003 DBMET02464 0.708 0.004 DBMET01611 0.858 0.003 DBMET01612 0.266 0.012 DBMET01613 0.413 0.007 DBMET02465 0.729 0.004 DBMET02456 0.747 0.004 DBMET02458 | DBMET02464 | |
| 0.886 | 0.003 | 0.892 | Dopamine antagonist | 0.786 0.003 DBMET02462 0.777 0.004 DBMET02463 0.892 0.003 DBMET02464 0.711 0.004 DBMET01611 0.848 0.003 DBMET01612 0.304 0.011 DBMET01613 0.456 0.006 DBMET02465 0.735 0.004 DBMET02456 0.724 0.004 DBMET02458 | DBMET02464 | |
| 0.83 | 0.003 | 0.83 | 5 Hydroxytryptamine 1A antagonist | 0.766 0.003 DBMET02462 0.645 0.004 DBMET02463 0.655 0.004 DBMET02464 0.628 0.004 DBMET01611 0.54 0.004 DBMET01612 0.297 0.009 DBMET01613 0.273 0.01 DBMET02465 0.639 0.004 DBMET02456 0.578 0.004 DBMET02458 | ||
| 0.823 | 0.003 | 0.823 | 5 Hydroxytryptamine 2 antagonist | 0.755 0.003 DBMET02462 0.726 0.004 DBMET02463 0.674 0.004 DBMET02464 0.713 0.004 DBMET01611 0.643 0.004 DBMET01612 0.433 0.008 DBMET01613 0.495 0.006 DBMET02465 0.683 0.004 DBMET02456 0.658 0.004 DBMET02458 | ||
| 0.817 | 0.003 | 0.817 | Alpha 1 adrenoreceptor antagonist | 0.732 0.003 DBMET02462 0.696 0.004 DBMET02463 0.779 0.003 DBMET02464 0.582 0.004 DBMET01611 0.664 0.004 DBMET01612 0.329 0.009 DBMET01613 0.37 0.008 DBMET02465 0.609 0.004 DBMET02456 0.662 0.004 DBMET02458 | ||
| 0.813 | 0.004 | 0.813 | 5 Hydroxytryptamine antagonist | 0.742 0.004 DBMET02462 0.716 0.004 DBMET02463 0.589 0.005 DBMET02464 0.675 0.004 DBMET01611 0.605 0.005 DBMET01612 0.48 0.008 DBMET01613 0.383 0.012 DBMET02465 0.704 0.004 DBMET02456 0.66 0.004 DBMET02458 | ||
| 0.81 | 0.003 | 0.81 | Alpha adrenoreceptor antagonist | 0.717 0.004 DBMET02462 0.68 0.004 DBMET02463 0.801 0.003 DBMET02464 0.536 0.005 DBMET01611 0.676 0.004 DBMET01612 0.377 0.01 DBMET01613 0.342 0.013 DBMET02465 0.621 0.004 DBMET02456 0.664 0.004 DBMET02458 | ||
| 0.782 | 0.003 | 0.782 | 5 Hydroxytryptamine 2A antagonist | 0.713 0.003 DBMET02462 0.68 0.003 DBMET02463 0.628 0.004 DBMET02464 0.671 0.003 DBMET01611 0.562 0.004 DBMET01612 0.379 0.008 DBMET01613 0.072 0.065 DBMET01614 0.494 0.005 DBMET02465 0.649 0.003 DBMET02456 0.591 0.004 DBMET02458 | ||
| 0.779 | 0.003 | 0.779 | 5 Hydroxytryptamine 1 antagonist | 0.714 0.003 DBMET02462 0.642 0.004 DBMET02463 0.579 0.004 DBMET02464 0.596 0.004 DBMET01611 0.594 0.004 DBMET01612 0.298 0.01 DBMET01613 0.228 0.014 DBMET02465 0.599 0.004 DBMET02456 0.648 0.004 DBMET02458 | ||
| 0.769 | 0.003 | 0.769 | Alpha 1a adrenoreceptor antagonist | 0.685 0.003 DBMET02462 0.65 0.004 DBMET02463 0.71 0.003 DBMET02464 0.513 0.004 DBMET01611 0.62 0.004 DBMET01612 0.3 0.009 DBMET01613 0.291 0.009 DBMET02465 0.513 0.004 DBMET02456 0.602 0.004 DBMET02458 | ||
| 0.696 | 0.001 | 0.696 | Dopamine autoreceptor agonist | 0.464 0.002 DBMET02462 0.495 0.002 DBMET02463 0.461 0.002 DBMET02464 0.559 0.001 DBMET01611 0.484 0.002 DBMET01612 0.052 0.007 DBMET01613 0.171 0.003 DBMET01614 0.148 0.003 DBMET02465 0.276 0.002 DBMET02456 0.489 0.002 DBMET02458 | ||
| 0.698 | 0.004 | 0.773 | Dopamine agonist | 0.601 0.004 DBMET02462 0.618 0.004 DBMET02463 0.694 0.004 DBMET02464 0.648 0.004 DBMET01611 0.667 0.004 DBMET01612 0.773 0.003 DBMET01613 0.104 0.026 DBMET01614 0.509 0.004 DBMET02465 0.139 0.016 DBMET02455 0.6 0.004 DBMET02456 0.649 0.004 DBMET02458 0.135 0.017 DBMET02466 0.143 0.016 DBMET02457 0.191 0.011 DBMET02459 | DBMET01613 | |
| 0.694 | 0.004 | 0.694 | 5 Hydroxytryptamine 2B antagonist | 0.487 0.005 DBMET02462 0.553 0.005 DBMET02463 0.549 0.005 DBMET02464 0.571 0.004 DBMET01611 0.554 0.005 DBMET01612 0.35 0.011 DBMET01613 0.235 0.021 DBMET02465 0.502 0.005 DBMET02456 0.567 0.004 DBMET02458 | ||
| 0.687 | 0.003 | 0.694 | Dopamine D2 agonist | 0.588 0.003 DBMET02462 0.591 0.003 DBMET02463 0.676 0.003 DBMET02464 0.626 0.003 DBMET01611 0.656 0.003 DBMET01612 0.694 0.003 DBMET01613 0.125 0.008 DBMET01614 0.495 0.004 DBMET02465 0.136 0.007 DBMET02455 0.575 0.003 DBMET02456 0.642 0.003 DBMET02458 0.133 0.007 DBMET02466 0.127 0.008 DBMET02457 0.199 0.005 DBMET02459 | DBMET01613 | |
| 0.617 | 0.004 | 0.617 | 5 Hydroxytryptamine 2C antagonist | 0.387 0.006 DBMET02462 0.532 0.004 DBMET02463 0.428 0.005 DBMET02464 0.587 0.004 DBMET01611 0.315 0.008 DBMET01612 0.412 0.005 DBMET01613 0.175 0.021 DBMET02465 0.462 0.005 DBMET02456 0.354 0.007 DBMET02458 | ||
| 0.588 | 0.003 | 0.588 | Alpha 1b adrenoreceptor antagonist | 0.385 0.005 DBMET02462 0.39 0.005 DBMET02463 0.537 0.004 DBMET02464 0.367 0.005 DBMET01611 0.436 0.004 DBMET01612 0.243 0.011 DBMET01613 0.206 0.014 DBMET02465 0.338 0.006 DBMET02456 0.424 0.005 DBMET02458 | ||
| 0.6 | 0.016 | 0.642 | Vasodilator, peripheral | 0.452 0.04 DBMET02462 0.464 0.036 DBMET02463 0.642 0.011 DBMET02464 0.562 0.02 DBMET01611 0.502 0.027 DBMET01612 0.375 0.064 DBMET01613 0.354 0.072 DBMET01614 0.413 0.051 DBMET02465 0.269 0.114 DBMET02456 0.486 0.031 DBMET02458 0.254 0.124 DBMET02460 | DBMET02464 | |
| 0.545 | 0.009 | 0.545 | Anticonvulsant | 0.275 0.048 DBMET02462 0.442 0.017 DBMET02463 0.316 0.036 DBMET02464 0.333 0.032 DBMET01611 0.307 0.039 DBMET01612 0.341 0.031 DBMET01613 0.146 0.135 DBMET02455 0.352 0.029 DBMET02458 0.142 0.139 DBMET02460 | ||
| 0.535 | 0.003 | 0.535 | Dopamine D3 antagonist | 0.322 0.005 DBMET02462 0.427 0.004 DBMET02463 0.473 0.004 DBMET02464 0.424 0.004 DBMET01611 0.351 0.005 DBMET01612 0.231 0.009 DBMET01613 0.18 0.012 DBMET02465 0.427 0.004 DBMET02456 0.289 0.006 DBMET02458 | ||
| 0.523 | 0.002 | 0.523 | 5 Hydroxytryptamine 7 agonist | 0.33 0.003 DBMET02462 0.328 0.003 DBMET02463 0.356 0.003 DBMET02464 0.256 0.003 DBMET01611 0.321 0.003 DBMET01612 0.142 0.004 DBMET01613 0.07 0.019 DBMET01614 0.108 0.006 DBMET02465 0.13 0.005 DBMET02456 0.347 0.003 DBMET02458 0.06 0.031 DBMET02460 | ||
| 0.513 | 0.003 | 0.858 | Dopamine D3 agonist | 0.386 0.003 DBMET02462 0.395 0.003 DBMET02463 0.428 0.003 DBMET02464 0.499 0.003 DBMET01611 0.41 0.003 DBMET01612 0.858 0.002 DBMET01613 0.329 0.003 DBMET02465 0.101 0.007 DBMET02455 0.428 0.003 DBMET02456 0.408 0.003 DBMET02458 0.082 0.009 DBMET02466 0.099 0.007 DBMET02457 0.088 0.008 DBMET02459 | DBMET01613 | |
| 0.483 | 0.004 | 0.56 | 5 Hydroxytryptamine 1A agonist | 0.344 0.005 DBMET02462 0.349 0.005 DBMET02463 0.364 0.005 DBMET02464 0.468 0.004 DBMET01611 0.368 0.005 DBMET01612 0.56 0.004 DBMET01613 0.272 0.006 DBMET02465 0.443 0.005 DBMET02456 0.432 0.005 DBMET02458 | DBMET01613 | |
| 0.475 | 0.005 | 0.664 | 5 Hydroxytryptamine 7 antagonist | 0.286 0.006 DBMET02462 0.293 0.006 DBMET02463 0.342 0.005 DBMET02464 0.448 0.005 DBMET01611 0.318 0.005 DBMET01612 0.664 0.004 DBMET01613 0.229 0.009 DBMET02465 0.382 0.005 DBMET02456 0.353 0.005 DBMET02458 | DBMET01613 | |
| 0.475 | 0.007 | 0.475 | Calcium channel activator | 0.413 0.02 DBMET02462 0.41 0.021 DBMET02463 0.445 0.012 DBMET02464 0.418 0.019 DBMET01611 0.437 0.014 DBMET01612 0.425 0.017 DBMET01613 0.377 0.034 DBMET01614 0.367 0.04 DBMET02465 0.338 0.058 DBMET02456 0.45 0.011 DBMET02458 0.409 0.021 DBMET02460 | ||
| 0.467 | 0.004 | 0.69 | Dopamine D1 antagonist | 0.278 0.007 DBMET02462 0.365 0.005 DBMET02463 0.69 0.003 DBMET02464 0.31 0.005 DBMET01611 0.521 0.003 DBMET01612 0.26 0.007 DBMET01613 0.237 0.008 DBMET02465 0.369 0.005 DBMET02456 0.292 0.006 DBMET02458 | DBMET02464 | |
| 0.442 | 0.004 | 0.605 | Dopamine D4 agonist | 0.343 0.004 DBMET02462 0.346 0.004 DBMET02463 0.375 0.004 DBMET02464 0.381 0.004 DBMET01611 0.343 0.004 DBMET01612 0.605 0.003 DBMET01613 0.285 0.005 DBMET02465 0.373 0.004 DBMET02456 0.367 0.004 DBMET02458 | DBMET01613 | |
| 0.437 | 0.007 | 0.551 | Antiadrenergic | 0.338 0.011 DBMET02462 0.321 0.012 DBMET02463 0.415 0.008 DBMET02464 0.376 0.009 DBMET01611 0.377 0.009 DBMET01612 0.551 0.005 DBMET01613 0.223 0.02 DBMET02465 0.365 0.01 DBMET02456 0.375 0.009 DBMET02458 | DBMET01613 | |
| 0.434 | 0.007 | 0.548 | Adrenaline antagonist | 0.335 0.011 DBMET02462 0.318 0.012 DBMET02463 0.411 0.008 DBMET02464 0.372 0.009 DBMET01611 0.374 0.009 DBMET01612 0.548 0.005 DBMET01613 0.219 0.02 DBMET02465 0.362 0.01 DBMET02456 0.372 0.009 DBMET02458 | DBMET01613 | |
| 0.387 | 0.004 | 0.387 | Alpha 1d adrenoreceptor antagonist | 0.202 0.009 DBMET02462 0.204 0.009 DBMET02463 0.305 0.005 DBMET02464 0.191 0.01 DBMET01611 0.226 0.008 DBMET01612 0.167 0.012 DBMET01613 0.1 0.023 DBMET02465 0.12 0.019 DBMET02456 0.226 0.008 DBMET02458 | ||
| 0.393 | 0.018 | 0.472 | Cyclic AMP phosphodiesterase inhibitor | 0.295 0.044 DBMET02462 0.333 0.03 DBMET02463 0.472 0.009 DBMET02464 0.371 0.021 DBMET01611 0.328 0.032 DBMET01612 0.182 0.109 DBMET01613 0.368 0.022 DBMET01614 0.154 0.146 DBMET02465 0.216 0.082 DBMET02456 0.32 0.034 DBMET02458 0.206 0.089 DBMET02460 | DBMET02464 | |
| 0.371 | 0.005 | 0.371 | Alpha 2b adrenoreceptor antagonist | 0.236 0.017 DBMET02462 0.295 0.009 DBMET02463 0.364 0.005 DBMET02464 0.231 0.018 DBMET01611 0.231 0.018 DBMET01612 0.284 0.01 DBMET01613 0.122 0.056 DBMET02465 0.231 0.018 DBMET02456 0.238 0.016 DBMET02458 | ||
| 0.371 | 0.005 | 0.429 | 5 Hydroxytryptamine 1 agonist | 0.259 0.008 DBMET02462 0.268 0.008 DBMET02463 0.262 0.008 DBMET02464 0.361 0.005 DBMET01611 0.285 0.007 DBMET01612 0.429 0.005 DBMET01613 0.151 0.014 DBMET02465 0.374 0.005 DBMET02456 0.323 0.005 DBMET02458 | DBMET01613 | |
| 0.369 | 0.004 | 0.369 | 5 Hydroxytryptamine 1B antagonist | 0.235 0.006 DBMET02462 0.233 0.007 DBMET02463 0.201 0.008 DBMET02464 0.251 0.006 DBMET01611 0.242 0.006 DBMET01612 0.187 0.009 DBMET01613 0.08 0.034 DBMET02465 0.148 0.013 DBMET02456 0.331 0.004 DBMET02458 | ||
| 0.422 | 0.067 | 0.515 | Calcium channel L-type activator | 0.397 0.083 DBMET02462 0.397 0.083 DBMET02463 0.418 0.069 DBMET02464 0.262 0.193 DBMET01611 0.435 0.059 DBMET01612 0.515 0.022 DBMET01614 0.275 0.18 DBMET02465 0.429 0.062 DBMET02458 0.257 0.197 DBMET02460 | DBMET01614 | |
| 0.372 | 0.027 | 0.372 | Psychostimulant | 0.24 0.062 DBMET02462 0.327 0.036 DBMET02463 0.348 0.032 DBMET02464 0.194 0.083 DBMET01611 0.244 0.061 DBMET01612 0.284 0.047 DBMET01613 0.22 0.07 DBMET01614 0.143 0.123 DBMET02465 0.144 0.122 DBMET02456 0.245 0.06 DBMET02458 0.192 0.085 DBMET02460 0.148 0.118 DBMET02461 | ||
| 0.347 | 0.004 | 0.347 | 5 Hydroxytryptamine 5A antagonist | 0.186 0.005 DBMET02462 0.201 0.005 DBMET02463 0.193 0.005 DBMET02464 0.25 0.004 DBMET01611 0.151 0.007 DBMET01612 0.195 0.005 DBMET01613 0.073 0.028 DBMET02465 0.151 0.007 DBMET02456 0.165 0.006 DBMET02458 | ||
| 0.402 | 0.077 | 0.581 | 5 Hydroxytryptamine release inhibitor | 0.324 0.139 DBMET02462 0.331 0.133 DBMET02463 0.371 0.098 DBMET02464 0.469 0.044 DBMET01611 0.318 0.146 DBMET01612 0.429 0.062 DBMET01613 0.345 0.119 DBMET01614 0.303 0.162 DBMET02465 0.439 0.057 DBMET02456 0.332 0.131 DBMET02458 0.581 0.014 DBMET02460 | DBMET02460 | |
| 0.325 | 0.006 | 0.403 | Alpha 2a adrenoreceptor antagonist | 0.177 0.017 DBMET02462 0.255 0.009 DBMET02463 0.403 0.005 DBMET02464 0.213 0.012 DBMET01611 0.187 0.016 DBMET01612 0.318 0.006 DBMET01613 0.088 0.043 DBMET02465 0.221 0.012 DBMET02456 0.172 0.018 DBMET02458 | DBMET02464 | |
| 0.308 | 0.006 | 0.32 | NMDA receptor antagonist | 0.137 0.028 DBMET02462 0.157 0.022 DBMET02463 0.32 0.005 DBMET02464 0.244 0.01 DBMET01611 0.273 0.008 DBMET01612 0.205 0.014 DBMET01613 0.077 0.069 DBMET02465 0.17 0.019 DBMET02455 0.089 0.055 DBMET02456 0.167 0.02 DBMET02458 0.078 0.069 DBMET02466 0.18 0.017 DBMET02457 0.115 0.038 DBMET02459 0.088 0.056 DBMET02460 | DBMET02464 | |
| 0.334 | 0.033 | 0.352 | Sigma receptor agonist | 0.184 0.067 DBMET02462 0.22 0.056 DBMET02463 0.305 0.038 DBMET02464 0.237 0.051 DBMET01611 0.227 0.054 DBMET01612 0.152 0.084 DBMET01613 0.278 0.043 DBMET02465 0.352 0.03 DBMET02456 0.236 0.052 DBMET02458 | DBMET02456 | |
| 0.296 | 0.008 | 0.639 | 5 Hydroxytryptamine agonist | 0.184 0.016 DBMET02462 0.212 0.013 DBMET02463 0.188 0.016 DBMET02464 0.242 0.011 DBMET01611 0.215 0.013 DBMET01612 0.639 0.004 DBMET01613 0.132 0.025 DBMET02465 0.315 0.008 DBMET02456 0.238 0.011 DBMET02458 | DBMET01613 | |
| 0.288 | 0.004 | 0.288 | 5 Hydroxytryptamine 5 antagonist | 0.164 0.006 DBMET02462 0.177 0.005 DBMET02463 0.158 0.007 DBMET02464 0.218 0.005 DBMET01611 0.129 0.01 DBMET01612 0.186 0.005 DBMET01613 0.06 0.037 DBMET02465 0.15 0.008 DBMET02456 0.143 0.008 DBMET02458 | ||
| 0.283 | 0.005 | 0.283 | 5 Hydroxytryptamine 1D antagonist | 0.172 0.009 DBMET02462 0.17 0.009 DBMET02463 0.154 0.011 DBMET02464 0.21 0.006 DBMET01611 0.177 0.008 DBMET01612 0.164 0.01 DBMET01613 0.06 0.049 DBMET02465 0.129 0.015 DBMET02456 0.259 0.005 DBMET02458 | ||
| 0.279 | 0.008 | 0.279 | Histamine H1 receptor antagonist | 0.158 0.022 DBMET02462 0.185 0.017 DBMET02463 0.154 0.023 DBMET02464 0.209 0.013 DBMET01611 0.135 0.028 DBMET01612 0.099 0.042 DBMET01613 0.071 0.067 DBMET02465 0.125 0.03 DBMET02456 0.124 0.031 DBMET02458 | ||
| 0.265 | 0.009 | 0.267 | Alpha 2c adrenoreceptor antagonist | 0.162 0.027 DBMET02462 0.204 0.017 DBMET02463 0.267 0.008 DBMET02464 0.17 0.025 DBMET01611 0.168 0.025 DBMET01612 0.218 0.015 DBMET01613 0.104 0.062 DBMET02465 0.182 0.022 DBMET02456 0.176 0.023 DBMET02458 | DBMET02464 | |
| 0.267 | 0.012 | 0.267 | Antihistaminic | 0.136 0.036 DBMET02462 0.167 0.028 DBMET02463 0.098 0.057 DBMET02464 0.259 0.013 DBMET01611 0.094 0.06 DBMET01612 0.098 0.056 DBMET01613 0.081 0.076 DBMET02465 0.136 0.037 DBMET02456 0.123 0.042 DBMET02458 | ||
| 0.298 | 0.05 | 0.491 | Potassium channel (Voltage-sensitive) blocker | 0.163 0.127 DBMET02462 0.215 0.085 DBMET02463 0.152 0.135 DBMET02464 0.329 0.041 DBMET01611 0.16 0.129 DBMET01612 0.491 0.015 DBMET01613 0.168 0.122 DBMET02456 0.196 0.099 DBMET02458 | DBMET01613 | |
| 0.259 | 0.012 | 0.259 | Histamine antagonist | 0.127 0.036 DBMET02462 0.157 0.028 DBMET02463 0.082 0.061 DBMET02464 0.253 0.013 DBMET01611 0.082 0.061 DBMET01612 0.089 0.055 DBMET01613 0.118 0.039 DBMET02456 0.11 0.043 DBMET02458 | ||
| 0.263 | 0.022 | 0.263 | Acetylcholine M1 receptor antagonist | 0.221 0.034 DBMET02462 0.197 0.044 DBMET02463 0.253 0.024 DBMET02464 0.257 0.023 DBMET01611 0.223 0.033 DBMET01612 0.194 0.045 DBMET01613 0.133 0.092 DBMET02456 0.181 0.051 DBMET02458 | ||
| 0.29 | 0.052 | 0.528 | HERG channel blocker | 0.159 0.121 DBMET02462 0.212 0.083 DBMET02463 0.154 0.127 DBMET02464 0.346 0.038 DBMET01611 0.163 0.117 DBMET01612 0.528 0.013 DBMET01613 0.17 0.11 DBMET02456 0.195 0.093 DBMET02458 | DBMET01613 | |
| 0.278 | 0.046 | 0.332 | 5 Hydroxytryptamine 1E antagonist | 0.234 0.092 DBMET02462 0.242 0.084 DBMET02463 0.263 0.06 DBMET02464 0.255 0.069 DBMET01611 0.202 0.128 DBMET01612 0.332 0.015 DBMET01613 0.198 0.133 DBMET02465 0.237 0.089 DBMET02456 0.222 0.106 DBMET02458 0.284 0.041 DBMET02460 | DBMET01613 | |
| 0.235 | 0.013 | 0.261 | Alpha 2 adrenoreceptor antagonist | 0.126 0.035 DBMET02462 0.191 0.019 DBMET02463 0.261 0.01 DBMET02464 0.146 0.028 DBMET01611 0.168 0.023 DBMET01612 0.255 0.011 DBMET01613 0.192 0.019 DBMET02456 0.167 0.023 DBMET02458 | DBMET02464 | |
| 0.266 | 0.044 | 0.285 | ErbB-1 antagonist | 0.226 0.066 DBMET02462 0.232 0.062 DBMET02463 0.285 0.037 DBMET02464 0.268 0.044 DBMET01611 0.246 0.053 DBMET01612 0.162 0.149 DBMET01613 0.226 0.066 DBMET01614 0.232 0.062 DBMET02456 0.239 0.058 DBMET02458 | DBMET02464 | |
| 0.291 | 0.095 | 0.338 | Vasodilator, coronary | 0.214 0.169 DBMET02463 0.315 0.076 DBMET02464 0.239 0.145 DBMET01611 0.291 0.095 DBMET01612 0.246 0.139 DBMET01613 0.26 0.124 DBMET01614 0.226 0.158 DBMET02465 0.275 0.109 DBMET02456 0.289 0.097 DBMET02458 0.338 0.061 DBMET02460 | DBMET02460 | |
| 0.267 | 0.077 | 0.267 | Ca(v)3.3 blocker | 0.236 0.123 DBMET02462 0.262 0.083 DBMET02463 0.224 0.144 DBMET02464 0.262 0.083 DBMET01611 0.235 0.125 DBMET01612 0.245 0.109 DBMET02465 0.246 0.107 DBMET02456 0.26 0.086 DBMET02458 | ||
| 0.25 | 0.059 | 0.336 | MAP-kinase-activated kinase 5 inhibitor | 0.228 0.075 DBMET02462 0.277 0.043 DBMET02463 0.263 0.052 DBMET02464 0.287 0.037 DBMET01611 0.22 0.082 DBMET01612 0.336 0.014 DBMET01613 0.17 0.148 DBMET02465 0.214 0.088 DBMET02456 0.222 0.08 DBMET02458 | DBMET01613 | |
| 0.248 | 0.058 | 0.282 | Neuropeptide Y2 antagonist | 0.202 0.116 DBMET02462 0.181 0.158 DBMET02463 0.206 0.11 DBMET02464 0.211 0.101 DBMET01611 0.193 0.132 DBMET01612 0.282 0.029 DBMET01613 0.185 0.15 DBMET02456 0.19 0.138 DBMET02458 0.232 0.074 DBMET02460 | DBMET01613 | |
| 0.186 | 0.011 | 0.187 | NMDA 2 receptor antagonist | 0.088 0.039 DBMET02462 0.102 0.031 DBMET02463 0.187 0.01 DBMET02464 0.153 0.016 DBMET01611 0.116 0.025 DBMET01612 0.138 0.019 DBMET01613 0.075 0.047 DBMET02458 | DBMET02464 | |
| 0.294 | 0.12 | 0.653 | GABA C receptor rho-3 antagonist | 0.284 0.127 DBMET02462 0.284 0.127 DBMET02463 0.427 0.05 DBMET01611 0.256 0.149 DBMET01612 0.547 0.015 DBMET01613 0.333 0.095 DBMET01614 0.366 0.078 DBMET02456 0.267 0.14 DBMET02458 0.653 0.004 DBMET02460 | DBMET02460 | |
| 0.18 | 0.007 | 0.18 | Alpha 1 adrenoreceptor agonist | 0.089 0.02 DBMET02462 0.091 0.019 DBMET02463 0.162 0.008 DBMET02464 0.105 0.015 DBMET01611 0.103 0.016 DBMET01612 0.141 0.01 DBMET01613 0.067 0.03 DBMET02456 0.103 0.016 DBMET02458 | ||
| 0.183 | 0.027 | 0.183 | Neuropeptide Y1 antagonist | 0.139 0.083 DBMET02462 0.141 0.079 DBMET02463 0.157 0.055 DBMET02464 0.143 0.075 DBMET01611 0.147 0.069 DBMET01612 0.172 0.037 DBMET01613 0.133 0.094 DBMET01614 0.132 0.096 DBMET02465 0.143 0.076 DBMET02458 0.135 0.09 DBMET02460 | ||
| 0.17 | 0.014 | 0.506 | 5 Hydroxytryptamine uptake inhibitor | 0.128 0.019 DBMET02462 0.119 0.021 DBMET02463 0.107 0.024 DBMET02464 0.173 0.013 DBMET01611 0.11 0.023 DBMET01612 0.506 0.004 DBMET01613 0.075 0.036 DBMET02465 0.203 0.011 DBMET02456 0.126 0.019 DBMET02458 0.056 0.05 DBMET02460 | DBMET01613 | |
| 0.327 | 0.178 | 0.51 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.275 0.249 DBMET02462 0.282 0.237 DBMET02463 0.307 0.203 DBMET01611 0.477 0.045 DBMET01613 0.372 0.127 DBMET01614 0.296 0.218 DBMET02458 0.51 0.029 DBMET02460 | DBMET02460 | |
| 0.163 | 0.014 | 0.22 | Alpha adrenoreceptor agonist | 0.15 0.016 DBMET02462 0.083 0.036 DBMET02463 0.172 0.012 DBMET02464 0.086 0.034 DBMET01611 0.086 0.034 DBMET01612 0.22 0.007 DBMET01613 0.078 0.039 DBMET02456 0.078 0.039 DBMET02458 | DBMET01613 | |
| 0.157 | 0.009 | 0.157 | Acetylcholine M4 receptor antagonist | 0.105 0.025 DBMET02462 0.113 0.02 DBMET02463 0.101 0.027 DBMET02464 0.078 0.048 DBMET01611 0.092 0.035 DBMET01612 0.109 0.022 DBMET01613 0.076 0.05 DBMET02456 0.108 0.023 DBMET02458 | ||
| 0.232 | 0.093 | 0.288 | Interleukin agonist | 0.253 0.076 DBMET02464 0.224 0.099 DBMET01612 0.273 0.063 DBMET01613 0.239 0.087 DBMET02465 0.225 0.099 DBMET02458 0.284 0.057 DBMET02466 0.288 0.054 DBMET02460 0.217 0.105 DBMET02461 | DBMET02460 | |
| 0.211 | 0.074 | 0.23 | Platelet aggregation inhibitor | 0.188 0.091 DBMET02462 0.167 0.11 DBMET02463 0.23 0.061 DBMET02464 0.211 0.074 DBMET01611 0.164 0.113 DBMET01614 | DBMET02464 | |
| 0.14 | 0.009 | 0.143 | Acetylcholine M5 receptor antagonist | 0.071 0.03 DBMET02462 0.083 0.023 DBMET02463 0.1 0.018 DBMET02464 0.143 0.008 DBMET01611 0.104 0.016 DBMET01612 0.081 0.024 DBMET01613 0.06 0.042 DBMET02456 0.083 0.023 DBMET02458 | DBMET01611 | |
| 0.151 | 0.028 | 0.201 | Mediator release inhibitor | 0.097 0.073 DBMET02462 0.123 0.045 DBMET02463 0.173 0.02 DBMET02464 0.201 0.014 DBMET01611 0.176 0.019 DBMET01612 0.117 0.05 DBMET02456 0.17 0.021 DBMET02458 0.112 0.056 DBMET02460 | DBMET01611 | |
| 0.129 | 0.008 | 0.17 | 5 Hydroxytryptamine 2A agonist | 0.095 0.017 DBMET02462 0.119 0.009 DBMET02463 0.091 0.019 DBMET02464 0.112 0.011 DBMET01611 0.076 0.031 DBMET01612 0.17 0.004 DBMET01613 0.056 0.051 DBMET01614 0.065 0.041 DBMET02465 0.092 0.018 DBMET02456 0.077 0.03 DBMET02458 0.073 0.034 DBMET02460 | DBMET01613 | |
| 0.222 | 0.104 | 0.303 | Spasmolytic | 0.175 0.141 DBMET02463 0.303 0.069 DBMET02464 0.243 0.094 DBMET01612 0.185 0.132 DBMET02458 0.19 0.128 DBMET02460 | DBMET02464 | |
| 0.163 | 0.05 | 0.21 | Nav1.2 sodium channel blocker | 0.109 0.098 DBMET02463 0.21 0.031 DBMET01611 0.127 0.075 DBMET01613 0.106 0.102 DBMET02460 | DBMET01611 | |
| 0.146 | 0.035 | 0.146 | Nav1.1 sodium channel blocker | 0.096 0.072 DBMET02462 0.111 0.055 DBMET02463 0.116 0.051 DBMET02464 0.118 0.049 DBMET01611 0.12 0.048 DBMET01612 0.097 0.07 DBMET02465 0.113 0.053 DBMET02458 | ||
| 0.193 | 0.082 | 0.277 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.169 0.105 DBMET02462 0.277 0.043 DBMET02463 0.185 0.089 DBMET02464 0.236 0.056 DBMET01611 0.181 0.093 DBMET01612 0.269 0.045 DBMET01613 0.163 0.112 DBMET02456 0.186 0.089 DBMET02458 0.156 0.12 DBMET02460 | DBMET02463 | |
| 0.131 | 0.021 | 0.166 | Adrenaline agonist | 0.117 0.027 DBMET02462 0.095 0.041 DBMET02463 0.166 0.011 DBMET02464 0.164 0.012 DBMET01611 0.165 0.012 DBMET01612 0.091 0.044 DBMET01613 0.082 0.056 DBMET02458 | DBMET02464 | |
| 0.155 | 0.048 | 0.19 | Glutamate receptor antagonist | 0.112 0.083 DBMET02462 0.138 0.059 DBMET02463 0.135 0.061 DBMET02464 0.147 0.053 DBMET01611 0.147 0.053 DBMET01612 0.19 0.029 DBMET01613 0.129 0.066 DBMET02458 | DBMET01613 | |
| 0.19 | 0.082 | 0.271 | 5 Hydroxytryptamine 3E antagonist | 0.175 0.121 DBMET02462 0.177 0.114 DBMET02463 0.2 0.062 DBMET01611 0.271 0.009 DBMET01613 0.192 0.078 DBMET01614 0.2 0.062 DBMET02456 0.172 0.129 DBMET02458 0.27 0.009 DBMET02460 | DBMET01613 | |
| 0.149 | 0.044 | 0.153 | Acetylcholine muscarinic antagonist | 0.119 0.068 DBMET02462 0.122 0.065 DBMET02463 0.136 0.053 DBMET02464 0.137 0.052 DBMET01611 0.153 0.042 DBMET01612 0.108 0.081 DBMET01613 0.104 0.086 DBMET02458 | DBMET01612 | |
| 0.199 | 0.093 | 0.289 | Potassium channel blocker | 0.246 0.068 DBMET02463 0.213 0.084 DBMET01611 0.289 0.05 DBMET01613 | DBMET01613 | |
| 0.141 | 0.036 | 0.186 | EphA2 antagonist | 0.118 0.056 DBMET02462 0.134 0.042 DBMET02463 0.153 0.029 DBMET02464 0.148 0.031 DBMET01611 0.097 0.079 DBMET01612 0.186 0.017 DBMET01613 0.12 0.054 DBMET02465 0.121 0.053 DBMET02456 | DBMET01613 | |
| 0.149 | 0.048 | 0.164 | Nav1.3 sodium channel blocker | 0.114 0.08 DBMET02463 0.164 0.039 DBMET01611 0.135 0.059 DBMET01613 | DBMET01611 | |
| 0.126 | 0.026 | 0.14 | Histamine N-methyltransferase inhibitor | 0.099 0.046 DBMET02462 0.122 0.028 DBMET02463 0.089 0.056 DBMET02464 0.137 0.019 DBMET01611 0.084 0.062 DBMET01612 0.14 0.018 DBMET01613 0.102 0.044 DBMET02456 0.079 0.068 DBMET02458 0.122 0.028 DBMET02460 | DBMET01613 | |
| 0.119 | 0.024 | 0.268 | 5 Hydroxytryptamine 1F antagonist | 0.08 0.043 DBMET02462 0.116 0.025 DBMET02463 0.084 0.04 DBMET02464 0.1 0.031 DBMET01611 0.075 0.046 DBMET01612 0.268 0.007 DBMET01613 0.088 0.038 DBMET02456 0.088 0.038 DBMET02458 | DBMET01613 | |
| 0.108 | 0.019 | 0.164 | Phosphodiesterase III inhibitor | 0.088 0.03 DBMET02462 0.086 0.03 DBMET02463 0.111 0.018 DBMET02464 0.139 0.012 DBMET01611 0.093 0.026 DBMET01612 0.164 0.009 DBMET01614 0.096 0.024 DBMET02458 | DBMET01614 | |
| 0.177 | 0.091 | 0.191 | Focal adhesion kinase 2 inhibitor | 0.163 0.11 DBMET01613 0.191 0.076 DBMET01614 0.147 0.136 DBMET02458 | DBMET01614 | |
| 0.129 | 0.043 | 0.16 | Butyrylcholinesterase inhibitor | 0.085 0.076 DBMET02462 0.16 0.03 DBMET02463 0.119 0.048 DBMET02464 0.11 0.054 DBMET01611 0.122 0.046 DBMET01612 0.097 0.064 DBMET02465 0.092 0.069 DBMET02456 0.15 0.034 DBMET02458 0.104 0.059 DBMET02460 | DBMET02463 | |
| 0.144 | 0.06 | 0.283 | Toll-Like receptor antagonist | 0.178 0.039 DBMET02464 0.26 0.013 DBMET01611 0.148 0.057 DBMET01612 0.283 0.009 DBMET01613 0.161 0.048 DBMET02458 0.129 0.073 DBMET02460 | DBMET01613 | |
| 0.099 | 0.016 | 0.113 | NMDA 2C receptor antagonist | 0.058 0.048 DBMET02462 0.068 0.035 DBMET02463 0.101 0.015 DBMET02464 0.064 0.039 DBMET01611 0.076 0.028 DBMET01612 0.113 0.012 DBMET01613 0.058 0.048 DBMET02455 0.061 0.043 DBMET02458 0.087 0.021 DBMET02457 0.07 0.033 DBMET02460 | DBMET01613 | |
| 0.154 | 0.074 | 0.209 | Cholinergic | 0.167 0.064 DBMET02462 0.169 0.063 DBMET02463 0.15 0.077 DBMET02464 0.13 0.096 DBMET01611 0.142 0.084 DBMET01612 0.209 0.042 DBMET01614 0.145 0.081 DBMET02465 0.166 0.065 DBMET02458 | DBMET01614 | |
| 0.139 | 0.059 | 0.139 | Cholinergic antagonist | 0.114 0.08 DBMET02462 0.109 0.084 DBMET02463 0.122 0.072 DBMET02464 0.134 0.062 DBMET01611 0.132 0.063 DBMET01612 0.116 0.078 DBMET01613 | ||
| 0.137 | 0.058 | 0.137 | Acetylcholine antagonist | 0.112 0.078 DBMET02462 0.108 0.082 DBMET02463 0.12 0.071 DBMET02464 0.133 0.06 DBMET01611 0.13 0.062 DBMET01612 0.114 0.076 DBMET01613 | ||
| 0.087 | 0.009 | 0.241 | Nicotinic acid receptor 1 agonist | 0.068 0.014 DBMET02462 0.063 0.015 DBMET02463 0.068 0.014 DBMET02464 0.241 0.003 DBMET01611 0.064 0.015 DBMET01612 0.195 0.004 DBMET01613 0.053 0.019 DBMET02465 0.036 0.034 DBMET02455 0.072 0.013 DBMET02456 0.068 0.013 DBMET02458 | DBMET01611 | |
| 0.113 | 0.036 | 0.121 | Interleukin 12 antagonist | 0.101 0.052 DBMET02462 0.097 0.058 DBMET02463 0.114 0.035 DBMET02464 0.085 0.084 DBMET01611 0.114 0.035 DBMET01612 0.121 0.028 DBMET01614 0.088 0.077 DBMET02456 0.109 0.04 DBMET02458 | DBMET01614 | |
| 0.094 | 0.017 | 0.094 | Sigma receptor antagonist | 0.047 0.036 DBMET02462 0.059 0.029 DBMET02463 0.073 0.022 DBMET02464 0.061 0.027 DBMET01611 0.063 0.026 DBMET01612 0.046 0.037 DBMET01613 0.058 0.029 DBMET02465 0.056 0.03 DBMET02456 0.06 0.028 DBMET02458 | ||
| 0.21 | 0.134 | 0.275 | Gastrin inhibitor | 0.268 0.06 DBMET01611 0.222 0.116 DBMET01613 0.185 0.171 DBMET02455 0.194 0.158 DBMET02458 0.275 0.053 DBMET02460 0.22 0.12 DBMET02461 | DBMET02460 | |
| 0.138 | 0.063 | 0.205 | Acetylcholinesterase inhibitor | 0.155 0.052 DBMET02462 0.156 0.052 DBMET02463 0.145 0.058 DBMET02464 0.131 0.069 DBMET01611 0.13 0.069 DBMET01612 0.205 0.032 DBMET01614 0.121 0.077 DBMET02465 0.152 0.054 DBMET02458 | DBMET01614 | |
| 0.167 | 0.093 | 0.186 | P-glycoprotein inhibitor | 0.139 0.135 DBMET02463 0.186 0.074 DBMET02464 0.15 0.117 DBMET01611 0.165 0.096 DBMET01612 0.167 0.093 DBMET02465 0.184 0.076 DBMET02456 0.17 0.089 DBMET02458 | DBMET02464 | |
| 0.086 | 0.014 | 0.149 | Phosphodiesterase 3B inhibitor | 0.058 0.02 DBMET02462 0.056 0.021 DBMET02463 0.091 0.013 DBMET02464 0.094 0.012 DBMET01611 0.08 0.015 DBMET01612 0.149 0.006 DBMET01614 0.076 0.016 DBMET02458 | DBMET01614 | |
| 0.098 | 0.029 | 0.167 | Cyclin B3 inhibitor | 0.084 0.036 DBMET02462 0.09 0.033 DBMET02463 0.106 0.026 DBMET02464 0.082 0.037 DBMET01611 0.104 0.027 DBMET01612 0.167 0.01 DBMET01613 0.059 0.058 DBMET01614 0.065 0.05 DBMET02456 0.084 0.036 DBMET02458 | DBMET01613 | |
| 0.081 | 0.012 | 0.081 | 5 Hydroxytryptamine 1B agonist | 0.069 0.018 DBMET02462 0.068 0.019 DBMET02463 0.065 0.022 DBMET02464 0.079 0.013 DBMET01611 0.069 0.018 DBMET01612 0.056 0.032 DBMET01613 0.07 0.018 DBMET01614 0.053 0.036 DBMET02456 0.077 0.013 DBMET02458 | ||
| 0.093 | 0.024 | 0.119 | Acetylcholine M5 receptor agonist | 0.074 0.04 DBMET02463 0.072 0.041 DBMET01611 0.092 0.025 DBMET01613 0.088 0.027 DBMET01614 0.094 0.024 DBMET02458 0.119 0.011 DBMET02460 | DBMET02460 | |
| 0.16 | 0.092 | 0.258 | Lipocortins synthesis antagonist | 0.153 0.1 DBMET02462 0.153 0.1 DBMET02463 0.18 0.071 DBMET02464 0.17 0.08 DBMET01612 0.258 0.031 DBMET01614 0.161 0.091 DBMET02465 0.179 0.072 DBMET02458 | DBMET01614 | |
| 0.133 | 0.068 | 0.141 | MAO inhibitor | 0.111 0.08 DBMET02464 0.119 0.075 DBMET01612 0.125 0.072 DBMET01614 0.141 0.064 DBMET02460 | DBMET02460 | |
| 0.183 | 0.119 | 0.226 | Vasodilator | 0.226 0.085 DBMET02464 0.154 0.151 DBMET01611 0.203 0.102 DBMET01612 0.222 0.088 DBMET01614 0.154 0.152 DBMET02455 0.169 0.133 DBMET02458 0.169 0.133 DBMET02466 0.193 0.11 DBMET02459 | DBMET02464 | |
| 0.076 | 0.015 | 0.076 | 5 Hydroxytryptamine 4 antagonist | 0.061 0.023 DBMET02463 0.054 0.03 DBMET02464 0.06 0.024 DBMET01611 0.059 0.024 DBMET01612 0.067 0.019 DBMET01613 0.05 0.039 DBMET02456 0.055 0.029 DBMET02458 | ||
| 0.076 | 0.017 | 0.221 | 5 Hydroxytryptamine 2 agonist | 0.053 0.035 DBMET02462 0.057 0.029 DBMET02463 0.049 0.039 DBMET01611 0.056 0.032 DBMET01612 0.221 0.004 DBMET01613 0.05 0.038 DBMET02456 0.05 0.038 DBMET02458 0.061 0.026 DBMET02460 | DBMET01613 | |
| 0.163 | 0.106 | 0.185 | MAP kinase kinase 5 inhibitor | 0.158 0.122 DBMET02462 0.158 0.122 DBMET02463 0.162 0.109 DBMET01611 0.152 0.146 DBMET01612 0.185 0.054 DBMET01614 0.153 0.14 DBMET02456 0.154 0.137 DBMET02458 | DBMET01614 | |
| 0.068 | 0.014 | 0.081 | Alpha 1L adrenoreceptor antagonist | 0.06 0.021 DBMET02462 0.06 0.022 DBMET02463 0.061 0.02 DBMET02464 0.081 0.007 DBMET01611 0.064 0.017 DBMET01612 0.053 0.035 DBMET02465 0.065 0.016 DBMET02456 0.066 0.015 DBMET02458 | DBMET01611 | |
| 0.069 | 0.015 | 0.085 | Dopamine D5 antagonist | 0.046 0.028 DBMET02462 0.058 0.02 DBMET02463 0.085 0.011 DBMET02464 0.054 0.023 DBMET01611 0.082 0.012 DBMET01612 0.037 0.035 DBMET01613 0.054 0.023 DBMET02465 0.081 0.012 DBMET02456 0.057 0.021 DBMET02458 | DBMET02464 | |
| 0.08 | 0.031 | 0.163 | 5 Hydroxytryptamine 3A antagonist | 0.077 0.034 DBMET02463 0.081 0.03 DBMET01611 0.163 0.004 DBMET01613 | DBMET01613 | |
| 0.1 | 0.051 | 0.102 | Phosphodiesterase 6D inhibitor | 0.089 0.08 DBMET02463 0.098 0.057 DBMET02464 0.088 0.082 DBMET01611 0.098 0.057 DBMET01612 0.102 0.048 DBMET01614 0.09 0.076 DBMET02458 0.087 0.085 DBMET02460 | DBMET01614 | |
| 0.272 | 0.226 | 0.661 | Caspase 9 stimulant | 0.333 0.16 DBMET02464 0.252 0.251 DBMET01611 0.355 0.142 DBMET01612 0.328 0.165 DBMET01613 0.39 0.117 DBMET01614 0.31 0.183 DBMET02456 0.348 0.147 DBMET02458 0.661 0.028 DBMET02460 | DBMET02460 | |
| 0.109 | 0.066 | 0.3 | 5 Hydroxytryptamine 3A agonist | 0.112 0.063 DBMET02463 0.133 0.046 DBMET01611 0.3 0.004 DBMET01613 0.125 0.052 DBMET02465 0.235 0.007 DBMET02460 | DBMET01613 | |
| 0.099 | 0.06 | 0.125 | MAO B inhibitor | 0.078 0.077 DBMET02464 0.092 0.065 DBMET01612 0.088 0.068 DBMET01614 0.125 0.048 DBMET02460 | DBMET02460 | |
| 0.106 | 0.068 | 0.142 | Protein kinase C gamma inhibitor | 0.125 0.048 DBMET02463 0.124 0.049 DBMET02464 0.116 0.056 DBMET01611 0.142 0.037 DBMET01613 0.128 0.046 DBMET01614 | DBMET01613 | |
| 0.074 | 0.036 | 0.284 | Purinergic P2 antagonist | 0.057 0.051 DBMET02463 0.081 0.032 DBMET01611 0.284 0.005 DBMET01613 | DBMET01613 | |
| 0.095 | 0.058 | 0.108 | Toll-Like receptor 3 antagonist | 0.089 0.071 DBMET02462 0.098 0.053 DBMET02463 0.108 0.04 DBMET01611 0.094 0.061 DBMET01614 0.092 0.065 DBMET02456 0.089 0.071 DBMET02458 | DBMET01611 | |
| 0.107 | 0.072 | 0.141 | Nav1.5 sodium channel blocker | 0.111 0.067 DBMET01611 0.141 0.033 DBMET01613 0.108 0.072 DBMET02460 | DBMET01613 | |
| 0.177 | 0.143 | 0.177 | Cardiotonic | 0.177 0.143 DBMET02464 | ||
| 0.098 | 0.064 | 0.098 | Insulin receptor antagonist | 0.093 0.071 DBMET01613 | ||
| 0.217 | 0.183 | 0.459 | Histamine release inhibitor | 0.303 0.122 DBMET02464 0.207 0.194 DBMET01611 0.224 0.177 DBMET01612 0.318 0.115 DBMET01614 0.227 0.174 DBMET02455 0.357 0.097 DBMET02456 0.208 0.193 DBMET02458 0.243 0.161 DBMET02457 0.459 0.045 DBMET02460 0.41 0.07 DBMET02461 | DBMET02460 | |
| 0.056 | 0.023 | 0.133 | Oleamide hydrolase inhibitor | 0.04 0.037 DBMET02463 0.133 0.005 DBMET01611 0.053 0.025 DBMET01613 0.042 0.035 DBMET01614 | DBMET01611 | |
| 0.193 | 0.16 | 0.241 | Thyroid hormone beta antagonist | 0.178 0.176 DBMET02464 0.2 0.153 DBMET01612 0.197 0.157 DBMET02458 0.241 0.124 DBMET02460 | DBMET02460 | |
| 0.062 | 0.029 | 0.062 | Melanin-concentrating hormone receptor 1 antagonist | 0.054 0.036 DBMET02463 0.053 0.037 DBMET01611 | ||
| 0.134 | 0.101 | 0.228 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.228 0.052 DBMET02463 0.127 0.108 DBMET02464 0.141 0.095 DBMET01611 0.128 0.108 DBMET01612 0.13 0.105 DBMET02458 | DBMET02463 | |
| 0.056 | 0.023 | 0.077 | Histamine H3 receptor antagonist | 0.077 0.017 DBMET01611 | DBMET01611 | |
| 0.07 | 0.039 | 0.087 | MDM2 inhibitor | 0.073 0.03 DBMET01611 0.082 0.018 DBMET01613 0.064 0.057 DBMET02456 0.087 0.013 DBMET02460 | DBMET02460 | |
| 0.195 | 0.166 | 0.248 | Thyroid hormone antagonist | 0.185 0.175 DBMET02464 0.212 0.151 DBMET01612 0.201 0.161 DBMET02458 0.248 0.125 DBMET02460 | DBMET02460 | |
| 0.128 | 0.099 | 0.128 | MAP3K9 inhibitor | 0.121 0.113 DBMET02462 0.122 0.11 DBMET02464 0.125 0.105 DBMET01612 0.123 0.108 DBMET01614 | ||
| 0.09 | 0.064 | 0.175 | Protein kinase C zeta inhibitor | 0.093 0.06 DBMET02463 0.114 0.037 DBMET02464 0.1 0.05 DBMET01611 0.094 0.059 DBMET01612 0.175 0.015 DBMET01613 0.083 0.08 DBMET02465 0.085 0.074 DBMET02456 0.095 0.057 DBMET02460 | DBMET01613 | |
| 0.072 | 0.046 | 0.126 | Amidase inhibitor | 0.126 0.014 DBMET01611 0.111 0.019 DBMET01613 | DBMET01611 | |
| 0.152 | 0.131 | 0.171 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.156 0.125 DBMET02463 0.171 0.105 DBMET02464 | DBMET02464 | |
| 0.032 | 0.012 | 0.035 | DNA polymerase III inhibitor | 0.028 0.019 DBMET02462 0.029 0.018 DBMET02463 0.03 0.016 DBMET02464 0.035 0.008 DBMET01611 0.027 0.024 DBMET01612 0.029 0.017 DBMET02465 0.029 0.017 DBMET02456 0.027 0.022 DBMET02458 | DBMET01611 | |
| 0.08 | 0.061 | 0.095 | Acetylcholine M3 receptor agonist | 0.085 0.056 DBMET01614 0.095 0.048 DBMET02465 0.074 0.067 DBMET02458 | DBMET02465 | |
| 0.077 | 0.059 | 0.101 | Platelet growth factor antagonist | 0.074 0.064 DBMET02463 0.086 0.051 DBMET02464 0.101 0.04 DBMET01611 | DBMET01611 | |
| 0.041 | 0.023 | 0.166 | 5 Hydroxytryptamine 2B agonist | 0.166 0.003 DBMET01613 0.046 0.016 DBMET02460 | DBMET01613 | |
| 0.039 | 0.023 | 0.048 | Delayed rectifier potassium channel blocker | 0.041 0.02 DBMET01611 0.036 0.029 DBMET02458 0.048 0.013 DBMET02460 | DBMET02460 | |
| 0.084 | 0.069 | 0.104 | ATPase (Vacuolar H+) inhibitor | 0.097 0.044 DBMET02464 0.104 0.035 DBMET01611 0.08 0.079 DBMET02456 | DBMET01611 | |
| 0.038 | 0.023 | 0.186 | Purinergic P2X7 antagonist | 0.031 0.03 DBMET02462 0.034 0.026 DBMET02463 0.034 0.027 DBMET01611 0.186 0.003 DBMET01613 | DBMET01613 | |
| 0.063 | 0.048 | 0.073 | Beta 3 adrenoreceptor antagonist | 0.071 0.032 DBMET02464 0.066 0.041 DBMET01611 0.071 0.032 DBMET01612 0.061 0.052 DBMET01614 0.073 0.03 DBMET02460 | DBMET02460 | |
| 0.064 | 0.05 | 0.106 | Bcl2 antagonist | 0.065 0.049 DBMET02464 0.065 0.048 DBMET01611 0.059 0.057 DBMET01613 0.081 0.031 DBMET02455 0.062 0.052 DBMET02466 0.079 0.033 DBMET02457 0.106 0.015 DBMET02459 0.087 0.026 DBMET02461 | DBMET02459 | |
| 0.059 | 0.045 | 0.255 | Adrenaline uptake inhibitor | 0.055 0.05 DBMET01611 0.255 0.005 DBMET01613 0.123 0.013 DBMET02460 | DBMET01613 | |
| 0.201 | 0.188 | 0.349 | Interleukin 2 agonist | 0.224 0.151 DBMET02464 0.224 0.151 DBMET01612 0.234 0.137 DBMET01614 0.222 0.154 DBMET02465 0.244 0.126 DBMET02455 0.2 0.19 DBMET02458 0.334 0.053 DBMET02466 0.251 0.117 DBMET02457 0.296 0.076 DBMET02459 0.349 0.046 DBMET02461 | DBMET02461 | |
| 0.068 | 0.055 | 0.071 | Calcium channel L-type blocker | 0.071 0.05 DBMET01611 | DBMET01611 | |
| 0.095 | 0.083 | 0.102 | Platelet activating factor antagonist | 0.096 0.082 DBMET02462 0.1 0.079 DBMET02464 0.102 0.076 DBMET01611 | DBMET01611 | |
| 0.085 | 0.075 | 0.134 | MAO A inhibitor | 0.083 0.077 DBMET02464 0.093 0.069 DBMET01612 0.134 0.046 DBMET01614 0.119 0.053 DBMET02460 | DBMET01614 | |
| 0.035 | 0.025 | 0.036 | Adenosine uptake inhibitor | 0.036 0.02 DBMET02464 0.034 0.028 DBMET02460 | DBMET02464 | |
| 0.074 | 0.065 | 0.091 | Phosphodiesterase 3A inhibitor | 0.076 0.061 DBMET02464 0.089 0.043 DBMET01611 0.091 0.04 DBMET01614 | DBMET01614 | |
| 0.043 | 0.034 | 0.319 | 5 Hydroxytryptamine 2C agonist | 0.319 0.003 DBMET01613 | DBMET01613 | |
| 0.056 | 0.048 | 0.056 | Acetylcholine M2 receptor antagonist | |||
| 0.045 | 0.038 | 0.224 | Purinergic P2X antagonist | 0.045 0.038 DBMET01611 0.224 0.004 DBMET01613 | DBMET01613 | |
| 0.052 | 0.045 | 0.176 | 5 Hydroxytryptamine 3 antagonist | 0.176 0.007 DBMET01613 | DBMET01613 | |
| 0.018 | 0.011 | 0.025 | 5-Alpha-reductase 1 inhibitor | 0.025 0.01 DBMET01614 0.015 0.013 DBMET02458 | DBMET01614 | |
| 0.013 | 0.01 | 0.015 | DNA polymerase III polC-type inhibitor | 0.015 0.006 DBMET01611 | DBMET01611 | |
| 0.053 | 0.05 | 0.067 | Acetylcholine M3 receptor antagonist | 0.067 0.034 DBMET01612 | DBMET01612 | |
| 0.061 | 0.064 | 0.073 | CXC chemokine receptor antagonist | 0.073 0.045 DBMET01613 | DBMET01613 | |
| 0.03 | 0.033 | 0.065 | 5 Hydroxytryptamine 3B antagonist | 0.065 0.01 DBMET01613 | DBMET01613 | |
| 0.105 | 0.108 | 0.108 | Calcium channel blocker | 0.108 0.103 DBMET01611 | DBMET01611 | |
| 0.095 | 0.099 | 0.141 | Acetylcholine release stimulant | 0.101 0.085 DBMET01613 0.141 0.023 DBMET02460 | DBMET02460 | |
| 0.031 | 0.035 | 0.041 | Ceramide glucosyltransferase inhibitor | 0.037 0.022 DBMET01611 0.037 0.022 DBMET01613 0.041 0.016 DBMET02460 | DBMET02460 | |
| 0.015 | 0.02 | 0.021 | 5-Alpha-reductase 2 inhibitor | 0.021 0.012 DBMET01614 | DBMET01614 | |
| 0.042 | 0.047 | 0.159 | Histamine H4 receptor antagonist | 0.159 0.004 DBMET01613 | DBMET01613 | |
| 0.03 | 0.035 | 0.049 | 5-Alpha-reductase inhibitor | 0.049 0.019 DBMET01614 0.036 0.027 DBMET02458 0.038 0.025 DBMET02460 | DBMET01614 | |
| 0.086 | 0.092 | 0.104 | Polo-like kinase-4 inhibitor | 0.104 0.073 DBMET01613 0.098 0.08 DBMET01614 | DBMET01613 | |
| 0.113 | 0.12 | 0.127 | Farnesoid X receptor antagonist | 0.127 0.088 DBMET02464 0.118 0.109 DBMET01612 | DBMET02464 | |
| 0.043 | 0.051 | 0.099 | CC chemokine receptor 2B antagonist | 0.047 0.037 DBMET01611 0.099 0.005 DBMET01613 | DBMET01613 | |
| 0.028 | 0.037 | 0.046 | Antidiuretic hormone antagonist | 0.046 0.024 DBMET02463 | DBMET02463 | |
| 0.08 | 0.089 | 0.19 | Glutamate release inhibitor | 0.125 0.019 DBMET01613 0.19 0.005 DBMET02460 | DBMET02460 | |
| 0.028 | 0.037 | 0.033 | Carnitine palmitoyltransferase 1 inhibitor | 0.033 0.025 DBMET02460 | DBMET02460 | |
| 0.027 | 0.038 | 0.032 | Carnitine palmitoyltransferase inhibitor | 0.032 0.026 DBMET02460 | DBMET02460 | |
| 0.045 | 0.056 | 0.157 | Dopamine uptake inhibitor | 0.055 0.043 DBMET01611 0.157 0.009 DBMET01613 0.067 0.032 DBMET02460 | DBMET01613 | |
| 0.038 | 0.05 | 0.059 | NMDA 2A receptor antagonist | 0.059 0.03 DBMET01613 0.05 0.037 DBMET02457 0.055 0.033 DBMET02460 0.044 0.043 DBMET02461 | DBMET01613 | |
| 0.08 | 0.092 | 0.146 | Lanosterol 14 alpha demethylase inhibitor | 0.146 0.013 DBMET01613 0.145 0.013 DBMET02460 | DBMET01613 | |
| 0.025 | 0.037 | 0.07 | Kainate receptor 2 antagonist | 0.07 0.009 DBMET01613 | DBMET01613 | |
| 0.054 | 0.067 | 0.069 | Beta adrenoreceptor antagonist | 0.069 0.039 DBMET02464 0.059 0.058 DBMET01611 0.066 0.045 DBMET01612 0.069 0.039 DBMET01614 | DBMET01614 | |
| 0.044 | 0.057 | 0.052 | Cyclin B2 inhibitor | 0.052 0.044 DBMET01613 | DBMET01613 | |
| 0.027 | 0.04 | 0.039 | Estrogen-related receptor beta antagonist | 0.032 0.024 DBMET02464 0.032 0.023 DBMET01612 0.039 0.012 DBMET01613 0.039 0.012 DBMET02456 | DBMET02456 | |
| 0.1 | 0.114 | 0.199 | Toll-Like receptor 9 antagonist | 0.199 0.036 DBMET01611 0.174 0.049 DBMET01613 0.141 0.069 DBMET02458 0.173 0.049 DBMET02460 | DBMET01611 | |
| 0.061 | 0.076 | 0.169 | Nicotinic alpha4beta2 receptor antagonist | 0.089 0.041 DBMET01611 0.169 0.005 DBMET01613 0.087 0.042 DBMET02460 | DBMET01613 | |
| 0.033 | 0.048 | 0.109 | NMDA receptor subunit 3B antagonist | 0.039 0.036 DBMET02464 0.109 0.01 DBMET01613 0.049 0.025 DBMET02460 | DBMET01613 | |
| 0.056 | 0.071 | 0.067 | Beta 2 adrenoreceptor agonist | 0.062 0.043 DBMET02464 0.067 0.025 DBMET01611 0.065 0.033 DBMET01612 | DBMET01611 | |
| 0.035 | 0.051 | 0.052 | Cannabinoid CB2 receptor antagonist | 0.052 0.035 DBMET01611 | DBMET01611 | |
| 0.047 | 0.064 | 0.068 | Cyclin B1 inhibitor | 0.068 0.034 DBMET01613 | DBMET01613 | |
| 0.064 | 0.081 | 0.114 | Calcium antagonist | 0.084 0.06 DBMET01611 0.114 0.038 DBMET01613 0.104 0.045 DBMET02456 0.103 0.046 DBMET02460 | DBMET01613 | |
| 0.023 | 0.04 | 0.029 | Lysophosphatidic acid 2 receptor antagonist | 0.029 0.023 DBMET02460 | DBMET02460 | |
| 0.021 | 0.039 | 0.03 | Vasopressin 1 antagonist | 0.03 0.024 DBMET02463 | DBMET02463 | |
| 0.174 | 0.195 | 0.572 | Immunomodulator | 0.217 0.144 DBMET02455 0.24 0.124 DBMET02466 0.572 0.014 DBMET02457 0.205 0.159 DBMET02459 | DBMET02457 | |
| 0.124 | 0.146 | 0.232 | DNA methylase inhibitor | 0.232 0.059 DBMET02464 0.175 0.097 DBMET01611 0.165 0.104 DBMET01612 0.136 0.131 DBMET02458 0.222 0.065 DBMET02460 0.194 0.083 DBMET02461 | DBMET02464 | |
| 0.052 | 0.075 | 0.103 | Cannabinoid receptor antagonist | 0.103 0.028 DBMET01611 0.078 0.041 DBMET01613 | DBMET01611 | |
| 0.042 | 0.065 | 0.188 | 5 Hydroxytryptamine 6 antagonist | 0.188 0.004 DBMET01613 | DBMET01613 | |
| 0.099 | 0.122 | 0.191 | Histone deacetylase SIRT1 inhibitor | 0.151 0.061 DBMET02455 0.164 0.051 DBMET02466 0.152 0.06 DBMET02457 0.168 0.048 DBMET02459 0.191 0.034 DBMET02461 | DBMET02461 | |
| 0.063 | 0.088 | 0.109 | Androgen antagonist | 0.08 0.065 DBMET02464 0.082 0.064 DBMET01612 0.085 0.06 DBMET01614 0.109 0.04 DBMET02460 | DBMET02460 | |
| 0.037 | 0.062 | 0.058 | Heme oxygenase inhibitor | 0.045 0.024 DBMET01613 0.058 0.007 DBMET02460 | DBMET02460 | |
| 0.063 | 0.09 | 0.087 | Estrogen receptor alpha antagonist | 0.072 0.062 DBMET02464 0.087 0.038 DBMET01612 0.073 0.061 DBMET02456 0.084 0.042 DBMET02460 | DBMET01612 | |
| 0.014 | 0.042 | 0.039 | Nociceptin (N/OFQ) receptor antagonist | 0.039 0.022 DBMET01613 | DBMET01613 | |
| 0.04 | 0.068 | 0.054 | Cyclin B inhibitor | 0.054 0.039 DBMET01613 | DBMET01613 | |
| 0.092 | 0.122 | 0.35 | Interleukin 2 antagonist | 0.133 0.029 DBMET01612 0.098 0.097 DBMET01614 0.124 0.039 DBMET02458 0.35 0.004 DBMET02460 | DBMET02460 | |
| 0.04 | 0.071 | 0.051 | Sodium/calcium exchanger inhibitor | 0.051 0.032 DBMET01611 | DBMET01611 | |
| 0.012 | 0.043 | 0.024 | Urotensin II antagonist | 0.024 0.013 DBMET01613 | DBMET01613 | |
| 0.083 | 0.114 | 0.097 | Multidrug resistance-associated protein 1 inhibitor | 0.097 0.084 DBMET02464 0.095 0.087 DBMET02456 | DBMET02464 | |
| 0.037 | 0.068 | 0.067 | Histamine agonist | 0.047 0.045 DBMET01611 0.067 0.021 DBMET01613 | DBMET01613 | |
| 0.119 | 0.151 | 0.309 | Anesthetic general | 0.142 0.122 DBMET02464 0.16 0.103 DBMET01613 0.138 0.128 DBMET01614 0.309 0.031 DBMET02460 | DBMET02460 | |
| 0.038 | 0.071 | 0.044 | Beta adrenoreceptor agonist | 0.044 0.038 DBMET01611 0.044 0.037 DBMET01612 | DBMET01612 | |
| 0.037 | 0.071 | 0.053 | Cannabinoid CB1 receptor agonist | 0.053 0.049 DBMET01613 | DBMET01613 | |
| 0.059 | 0.094 | 0.068 | Phosphodiesterase VI inhibitor | 0.068 0.067 DBMET01611 | DBMET01611 | |
| 0.033 | 0.067 | 0.05 | Potassium channel small-conductance Ca-activated blocker | 0.05 0.024 DBMET01613 | DBMET01613 | |
| 0.167 | 0.203 | 0.284 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.284 0.076 DBMET02463 0.187 0.173 DBMET02464 0.207 0.15 DBMET01611 0.23 0.125 DBMET01613 | DBMET02463 | |
| 0.093 | 0.129 | 0.127 | Sphingosine 1-phosphate receptor 2 agonist | 0.127 0.045 DBMET01613 | DBMET01613 | |
| 0.089 | 0.125 | 0.269 | Estrogen antagonist | 0.111 0.072 DBMET02464 0.135 0.032 DBMET01612 0.101 0.096 DBMET02456 0.117 0.061 DBMET02458 0.269 0.008 DBMET02460 | DBMET02460 | |
| 0.033 | 0.07 | 0.04 | DNA gyrase subunit A inhibitor | 0.04 0.036 DBMET02465 | DBMET02465 | |
| 0.115 | 0.152 | 0.229 | DNA methyltransferase I inhibitor | 0.22 0.06 DBMET02464 0.152 0.101 DBMET01611 0.145 0.11 DBMET01612 0.229 0.056 DBMET02460 0.163 0.091 DBMET02461 | DBMET02460 | |
| 0.046 | 0.084 | 0.113 | Potassium channel (Ca-activated) blocker | 0.113 0.007 DBMET02463 | DBMET02463 | |
| 0.014 | 0.052 | 0.026 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.023 0.009 DBMET01613 0.026 0.006 DBMET02460 | DBMET02460 | |
| 0.094 | 0.132 | 0.14 | Nav1.6 sodium channel blocker | 0.14 0.066 DBMET02460 | DBMET02460 | |
| 0.069 | 0.108 | 0.076 | Ca(v)3.1 blocker | 0.076 0.073 DBMET01611 | DBMET01611 | |
| 0.067 | 0.108 | 0.143 | Chemokine receptor antagonist | 0.143 0.035 DBMET01613 | DBMET01613 | |
| 0.021 | 0.062 | 0.076 | NMDA receptor subunit 3A antagonist | 0.076 0.013 DBMET01613 0.041 0.025 DBMET02460 | DBMET01613 | |
| 0.09 | 0.132 | 0.321 | NADPH oxidase inhibitor | 0.135 0.066 DBMET02464 0.169 0.045 DBMET01613 0.321 0.01 DBMET01614 0.185 0.039 DBMET02460 | DBMET01614 | |
| 0.035 | 0.077 | 0.052 | Beta 1 adrenoreceptor antagonist | 0.049 0.048 DBMET01613 0.052 0.044 DBMET01614 | DBMET01614 | |
| 0.023 | 0.067 | 0.058 | Vascular adhesion protein 1 inhibitor | 0.058 0.01 DBMET01613 | DBMET01613 | |
| 0.012 | 0.056 | 0.021 | CC chemokine 1 receptor antagonist | 0.021 0.019 DBMET01613 | DBMET01613 | |
| 0.008 | 0.053 | 0.019 | Cyclin D2 inhibitor | 0.019 0.004 DBMET01613 | DBMET01613 | |
| 0.04 | 0.084 | 0.062 | Calcium channel T-type blocker | 0.062 0.034 DBMET01613 | DBMET01613 | |
| 0.018 | 0.062 | 0.033 | Glutamate (mGluR2) antagonist | 0.033 0.017 DBMET02460 | DBMET02460 | |
| 0.067 | 0.113 | 0.288 | Creatine kinase inhibitor | 0.106 0.053 DBMET02464 0.105 0.054 DBMET01611 0.087 0.075 DBMET01612 0.116 0.044 DBMET01613 0.288 0.004 DBMET02460 | DBMET02460 | |
| 0.052 | 0.099 | 0.133 | Phospholipase D inhibitor | 0.074 0.045 DBMET01611 0.133 0.004 DBMET01613 0.096 0.017 DBMET02460 | DBMET01613 | |
| 0.082 | 0.131 | 0.152 | Bone formation stimulant | 0.127 0.08 DBMET01614 0.118 0.088 DBMET02455 0.113 0.092 DBMET02466 0.122 0.084 DBMET02457 0.142 0.066 DBMET02459 0.152 0.057 DBMET02461 | DBMET02461 | |
| 0.039 | 0.09 | 0.082 | Cyclin D1 inhibitor | 0.075 0.023 DBMET01611 0.082 0.016 DBMET01613 0.059 0.045 DBMET01614 0.075 0.023 DBMET02460 | DBMET01613 | |
| 0.02 | 0.071 | 0.03 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.026 0.019 DBMET01613 0.03 0.011 DBMET02460 | DBMET02460 | |
| 0.058 | 0.11 | 0.088 | Acetylcholine agonist | 0.088 0.057 DBMET01613 | DBMET01613 | |
| 0.022 | 0.074 | 0.046 | Glutamate (mGluR group II) antagonist | 0.046 0.019 DBMET02460 | DBMET02460 | |
| 0.038 | 0.092 | 0.087 | Nicotinic alpha3beta2 receptor antagonist | 0.087 0.01 DBMET01613 0.066 0.02 DBMET02460 | DBMET01613 | |
| 0.012 | 0.067 | 0.027 | Acetylcholine M4 receptor agonist | 0.027 0.025 DBMET01613 | DBMET01613 | |
| 0.079 | 0.135 | 0.138 | Epidermal growth factor receptor kinase inhibitor | 0.138 0.057 DBMET02460 | DBMET02460 | |
| 0.065 | 0.122 | 0.074 | MAP kinase 7 inhibitor | 0.074 0.07 DBMET01613 | DBMET01613 | |
| 0.074 | 0.132 | 0.105 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.105 0.096 DBMET02463 | DBMET02463 | |
| 0.026 | 0.085 | 0.055 | Nicotinic receptor alpha3 subunit antagonist | 0.055 0.022 DBMET01613 | DBMET01613 | |
| 0.083 | 0.143 | 0.127 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.127 0.095 DBMET01613 | DBMET01613 | |
| 0.029 | 0.089 | 0.059 | Integrin alpha1beta1 antagonist | 0.059 0.005 DBMET01613 0.04 0.021 DBMET02461 | DBMET01613 | |
| 0.155 | 0.216 | 0.43 | Cholesterol antagonist | 0.184 0.18 DBMET02464 0.215 0.152 DBMET01613 0.207 0.159 DBMET01614 0.43 0.044 DBMET02460 | DBMET02460 | |
| 0.018 | 0.081 | 0.037 | Estrogen-related receptor gamma antagonist | 0.037 0.007 DBMET01613 0.031 0.014 DBMET02460 | DBMET01613 | |
| 0.063 | 0.126 | 0.138 | Falcipain 3 inhibitor | 0.138 0.043 DBMET01614 0.118 0.055 DBMET02460 | DBMET01614 | |
| 0.079 | 0.143 | 0.193 | Ribosomal protein S6 kinase inhibitor | 0.193 0.04 DBMET01613 | DBMET01613 | |
| 0.024 | 0.088 | 0.043 | Acid-sensing ion channel blocker | 0.043 0.024 DBMET01613 | DBMET01613 | |
| 0.08 | 0.145 | 0.114 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.114 0.089 DBMET02463 | DBMET02463 | |
| 0.023 | 0.09 | 0.037 | Protein kinase C beta I inhibitor | 0.037 0.014 DBMET02463 | DBMET02463 | |
| 0.034 | 0.102 | 0.108 | Androgen agonist | 0.058 0.044 DBMET01613 0.108 0.012 DBMET02460 | DBMET02460 | |
| 0.009 | 0.078 | 0.034 | NMDA receptor glycine site antagonist | 0.034 0.01 DBMET01613 0.03 0.012 DBMET02460 | DBMET01613 | |
| 0.009 | 0.079 | 0.022 | Kainate receptor 4 antagonist | 0.022 0.02 DBMET01613 | DBMET01613 | |
| 0.121 | 0.193 | 0.141 | Death-associated protein kinase 2 inhibitor | 0.141 0.128 DBMET02464 | DBMET02464 | |
| 0.136 | 0.209 | 0.623 | 5 Hydroxytryptamine release stimulant | 0.623 0.012 DBMET01613 0.604 0.014 DBMET02460 | DBMET01613 | |
| 0.049 | 0.122 | 0.099 | Macrophage migration inhibitory factor inhibitor | 0.07 0.067 DBMET02464 0.099 0.035 DBMET02460 | DBMET02460 | |
| 0.033 | 0.107 | 0.054 | Phosphodiesterase 7A inhibitor | 0.054 0.031 DBMET01611 0.052 0.035 DBMET01613 | DBMET01611 | |
| 0.056 | 0.131 | 0.079 | Hepatocyte growth factor antagonist | 0.079 0.076 DBMET01611 | DBMET01611 | |
| 0.02 | 0.094 | 0.037 | Protein kinase C beta II inhibitor | 0.037 0.014 DBMET02463 | DBMET02463 | |
| 0.025 | 0.1 | 0.067 | Nerve growth factor antagonist | 0.067 0.006 DBMET01613 0.056 0.012 DBMET02460 | DBMET01613 | |
| 0.064 | 0.14 | 0.179 | Estrogen receptor beta antagonist | 0.093 0.078 DBMET02464 0.113 0.042 DBMET01612 0.089 0.085 DBMET02456 0.09 0.083 DBMET02458 0.179 0.012 DBMET02460 | DBMET02460 | |
| 0.02 | 0.096 | 0.041 | Cholecystokinin B agonist | 0.035 0.031 DBMET02459 0.041 0.022 DBMET02461 | DBMET02461 | |
| 0.063 | 0.139 | 0.086 | Thioredoxin reductase inhibitor | 0.086 0.047 DBMET01614 0.083 0.055 DBMET02460 | DBMET01614 | |
| 0.025 | 0.102 | 0.063 | Phenylethanolamine N methyltransferase inhibitor | 0.063 0.006 DBMET01613 | DBMET01613 | |
| 0.13 | 0.208 | 0.196 | DNA damaging | 0.178 0.136 DBMET02464 0.176 0.139 DBMET01611 0.196 0.119 DBMET02460 | DBMET02460 | |
| 0.047 | 0.126 | 0.152 | ALK inhibitor | 0.152 0.019 DBMET01613 | DBMET01613 | |
| 0.058 | 0.138 | 0.103 | Ephrin antagonist | 0.103 0.06 DBMET01613 | DBMET01613 | |
| 0.065 | 0.145 | 0.169 | Hematopoietic | 0.101 0.035 DBMET02455 0.12 0.022 DBMET02466 0.097 0.039 DBMET02457 0.107 0.03 DBMET02459 0.169 0.013 DBMET02461 | DBMET02461 | |
| 0.03 | 0.11 | 0.08 | Alpha 1L adrenoreceptor agonist | 0.08 0.004 DBMET01613 0.053 0.014 DBMET02460 | DBMET01613 | |
| 0.045 | 0.126 | 0.107 | Acetylcholine nicotinic antagonist | 0.107 0.035 DBMET01613 | DBMET01613 | |
| 0.01 | 0.092 | 0.037 | AMPA 2 receptor antagonist | 0.037 0.016 DBMET01613 | DBMET01613 | |
| 0.042 | 0.126 | 0.061 | Leukotriene C antagonist | 0.061 0.027 DBMET02460 | DBMET02460 | |
| 0.067 | 0.151 | 0.145 | Beta glucuronidase inhibitor | 0.093 0.082 DBMET02464 0.145 0.027 DBMET01613 0.129 0.038 DBMET02460 | DBMET01613 | |
| 0.01 | 0.095 | 0.068 | Leukotriene A4 hydrolase inhibitor | 0.061 0.015 DBMET02455 0.043 0.024 DBMET02466 0.054 0.018 DBMET02457 0.047 0.022 DBMET02459 0.068 0.012 DBMET02461 | DBMET02461 | |
| 0.019 | 0.105 | 0.043 | Growth hormone release inhibitor | 0.043 0.028 DBMET02461 | DBMET02461 | |
| 0.112 | 0.199 | 0.28 | Platelet antagonist | 0.226 0.084 DBMET02455 0.232 0.081 DBMET02466 0.197 0.103 DBMET02457 0.237 0.078 DBMET02459 0.28 0.06 DBMET02461 | DBMET02461 | |
| 0.028 | 0.115 | 0.095 | Purinergic P2X4 antagonist | 0.095 0.005 DBMET01613 0.061 0.014 DBMET02460 | DBMET01613 | |
| 0.034 | 0.121 | 0.097 | Neuronal nicotinic receptor antagonist | 0.097 0.026 DBMET01613 | DBMET01613 | |
| 0.107 | 0.194 | 0.148 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.138 0.125 DBMET02463 0.148 0.114 DBMET01613 | DBMET01613 | |
| 0.023 | 0.111 | 0.08 | Dopamine transporter inhibitor | 0.08 0.017 DBMET01613 0.063 0.024 DBMET02460 | DBMET01613 | |
| 0.053 | 0.141 | 0.074 | Neuropeptide Y antagonist | 0.074 0.07 DBMET01613 | DBMET01613 | |
| 0.017 | 0.105 | 0.053 | Cyclin D3 inhibitor | 0.053 0.02 DBMET01613 | DBMET01613 | |
| 0.031 | 0.12 | 0.168 | Alpha 2 adrenoreceptor agonist | 0.168 0.005 DBMET01613 | DBMET01613 | |
| 0.013 | 0.103 | 0.032 | Histone deacetylase class IV inhibitor | 0.032 0.021 DBMET01614 | DBMET01614 | |
| 0.013 | 0.103 | 0.032 | Histone deacetylase 11 inhibitor | 0.032 0.021 DBMET01614 | DBMET01614 | |
| 0.102 | 0.191 | 0.174 | Sphingosine 1-phosphate receptor 5 antagonist | 0.129 0.102 DBMET01611 0.133 0.095 DBMET01613 0.174 0.029 DBMET02460 | DBMET02460 | |
| 0.033 | 0.123 | 0.058 | Bombesin 1 receptor agonist | 0.058 0.044 DBMET02461 | DBMET02461 | |
| 0.132 | 0.221 | 0.432 | Superoxide dismutase inhibitor | 0.189 0.129 DBMET02464 0.18 0.141 DBMET01611 0.403 0.026 DBMET01613 0.21 0.107 DBMET01614 0.432 0.021 DBMET02460 0.257 0.07 DBMET02461 | DBMET02460 | |
| 0.048 | 0.138 | 0.091 | Insulin like growth factor 1 antagonist | 0.091 0.049 DBMET01613 | DBMET01613 | |
| 0.027 | 0.118 | 0.059 | Cholesterol esterase inhibitor | 0.059 0.018 DBMET02460 | DBMET02460 | |
| 0.105 | 0.197 | 0.698 | Aldehyde oxidase inhibitor | 0.197 0.106 DBMET02464 0.321 0.061 DBMET01613 0.698 0.008 DBMET02460 | DBMET02460 | |
| 0.052 | 0.145 | 0.075 | Cell adhesion molecule inhibitor | 0.073 0.064 DBMET01613 0.075 0.061 DBMET02461 | DBMET02461 | |
| 0.02 | 0.115 | 0.05 | Somatostatin 4 agonist | 0.05 0.015 DBMET01613 | DBMET01613 | |
| 0.046 | 0.143 | 0.096 | Insulin growth factor antagonist | 0.096 0.049 DBMET01613 | DBMET01613 | |
| 0.027 | 0.125 | 0.075 | Nicotinic receptor alpha4 subunit antagonist | 0.075 0.015 DBMET01613 | DBMET01613 | |
| 0.047 | 0.146 | 0.129 | MAP-kinase-activated kinase inhibitor | 0.129 0.022 DBMET01613 | DBMET01613 | |
| 0.027 | 0.125 | 0.04 | Leukotriene C4 antagonist | 0.04 0.024 DBMET02460 | DBMET02460 | |
| 0.025 | 0.124 | 0.069 | CC chemokine 4 receptor antagonist | 0.069 0.01 DBMET01613 0.057 0.019 DBMET02460 | DBMET01613 | |
| 0.046 | 0.146 | 0.072 | Interferon agonist | 0.072 0.066 DBMET02460 | DBMET02460 | |
| 0.063 | 0.164 | 0.114 | AMP-activated protein kinase stimulant | 0.092 0.082 DBMET01613 0.114 0.054 DBMET02460 | DBMET02460 | |
| 0.091 | 0.193 | 0.166 | Polo-like kinase-3 inhibitor | 0.166 0.068 DBMET01613 | DBMET01613 | |
| 0.017 | 0.119 | 0.076 | Glycine transporter 2 inhibitor | 0.058 0.026 DBMET02455 0.063 0.024 DBMET02457 0.076 0.019 DBMET02461 | DBMET02461 | |
| 0.023 | 0.126 | 0.045 | Thymidine kinase inhibitor | 0.045 0.023 DBMET02460 | DBMET02460 | |
| 0.067 | 0.173 | 0.125 | Glutamate (mGluR7) agonist | 0.114 0.038 DBMET01613 0.125 0.026 DBMET02460 | DBMET02460 | |
| 0.045 | 0.151 | 0.103 | Epidermal growth factor antagonist | 0.103 0.043 DBMET02463 | DBMET02463 | |
| 0.157 | 0.264 | 0.412 | Antiobesity | 0.412 0.061 DBMET01613 | DBMET01613 | |
| 0.093 | 0.2 | 0.275 | GABA C receptor rho-2 antagonist | 0.124 0.117 DBMET01611 0.205 0.026 DBMET01613 0.131 0.104 DBMET01614 0.275 0.008 DBMET02460 | DBMET02460 | |
| 0.009 | 0.116 | 0.042 | Sirtuin 2 inhibitor | 0.042 0.016 DBMET02460 | DBMET02460 | |
| 0.05 | 0.158 | 0.152 | Sphingomyelinase inhibitor | 0.152 0.024 DBMET02460 | DBMET02460 | |
| 0.107 | 0.215 | 0.208 | ATPase inhibitor | 0.18 0.058 DBMET01611 0.158 0.089 DBMET01613 0.208 0.031 DBMET02460 | DBMET02460 | |
| 0.017 | 0.126 | 0.044 | GABA uptake inhibitor | 0.044 0.021 DBMET02460 | DBMET02460 | |
| 0.039 | 0.149 | 0.109 | MAP-kinase-activated kinase 2 inhibitor | 0.109 0.024 DBMET01613 | DBMET01613 | |
| 0.146 | 0.258 | 0.284 | Antithrombotic | 0.284 0.1 DBMET01614 0.257 0.121 DBMET02466 0.216 0.158 DBMET02460 0.246 0.129 DBMET02461 | DBMET01614 | |
| 0.113 | 0.226 | 0.175 | Neurotensin receptor agonist | 0.169 0.064 DBMET01613 0.175 0.055 DBMET02460 0.174 0.057 DBMET02461 | DBMET02460 | |
| 0.019 | 0.132 | 0.048 | Acetylcholine muscarinic agonist | 0.048 0.045 DBMET02460 | DBMET02460 | |
| 0.069 | 0.183 | 0.576 | Aldehyde dehydrogenase inhibitor | 0.576 0.004 DBMET01614 0.23 0.021 DBMET02460 | DBMET01614 | |
| 0.004 | 0.119 | 0.021 | Kainate receptor 1 antagonist | 0.021 0.015 DBMET01613 | DBMET01613 | |
| 0.051 | 0.167 | 0.093 | Caspase 7 inhibitor | 0.082 0.057 DBMET01613 0.093 0.037 DBMET02460 | DBMET02460 | |
| 0.036 | 0.154 | 0.102 | Corticotropin releasing factor 2 receptor antagonist | 0.102 0.006 DBMET01613 0.082 0.015 DBMET02460 | DBMET01613 | |
| 0.011 | 0.129 | 0.06 | Nicotinic acid receptor agonist | 0.035 0.026 DBMET01613 0.06 0.011 DBMET02460 | DBMET02460 | |
| 0.147 | 0.267 | 0.301 | Alpha-glucosidase inhibitor | 0.257 0.183 DBMET02464 0.301 0.159 DBMET02460 | DBMET02460 | |
| 0.013 | 0.135 | 0.046 | CC chemokine 3 receptor antagonist | 0.046 0.026 DBMET01613 | DBMET01613 | |
| 0.047 | 0.17 | 0.092 | Anesthetic local | 0.092 0.091 DBMET02460 | DBMET02460 | |
| 0.024 | 0.148 | 0.059 | Phosphodiesterase VII inhibitor | 0.057 0.05 DBMET01611 0.059 0.048 DBMET01613 | DBMET01613 | |
| 0.002 | 0.126 | 0.01 | Melatonin 5 antagonist | 0.01 0.009 DBMET01613 | DBMET01613 | |
| 0.055 | 0.179 | 0.084 | Polo-like kinase-1 inhibitor | 0.084 0.073 DBMET02460 | DBMET02460 | |
| 0.182 | 0.307 | 0.372 | MAP kinase kinase 6 inhibitor | 0.372 0.076 DBMET02463 0.247 0.195 DBMET01613 | DBMET02463 | |
| 0.004 | 0.13 | 0.035 | AMPA 1 receptor antagonist | 0.035 0.017 DBMET01613 | DBMET01613 | |
| 0.074 | 0.204 | 0.176 | Amyloid beta aggregation inhibitor | 0.176 0.091 DBMET02464 | DBMET02464 | |
| 0.132 | 0.262 | 0.267 | Calpain 2 inhibitor | 0.225 0.167 DBMET01613 0.221 0.17 DBMET01614 0.267 0.138 DBMET02460 | DBMET02460 | |
| 0.046 | 0.176 | 0.077 | Antineoplastic alkaloid | 0.077 0.069 DBMET02466 | DBMET02466 | |
| 0.02 | 0.151 | 0.137 | Toll-Like receptor 8 antagonist | 0.137 0.004 DBMET01613 | DBMET01613 | |
| 0.032 | 0.162 | 0.155 | 5 Hydroxytryptamine 3 agonist | 0.155 0.005 DBMET01613 0.081 0.026 DBMET02460 | DBMET01613 | |
| 0.026 | 0.157 | 0.073 | Cannabinoid CB1 receptor antagonist | 0.058 0.047 DBMET01611 0.073 0.032 DBMET01613 | DBMET01613 | |
| 0.165 | 0.296 | 0.286 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.286 0.033 DBMET02463 0.202 0.161 DBMET01613 | DBMET02463 | |
| 0.091 | 0.226 | 0.151 | Tumour necrosis factor antagonist | 0.151 0.099 DBMET02460 | DBMET02460 | |
| 0.028 | 0.164 | 0.084 | Glutamate receptor agonist | 0.084 0.049 DBMET02460 | DBMET02460 | |
| 0.024 | 0.161 | 0.058 | Glutamate (mGluR4) antagonist | 0.058 0.015 DBMET02460 | DBMET02460 | |
| 0.046 | 0.182 | 0.094 | Calcium channel P-type blocker | 0.094 0.007 DBMET02460 | DBMET02460 | |
| 0.042 | 0.18 | 0.098 | Granulocyte macrophage colony stimulating factor antagonist | 0.098 0.074 DBMET01613 | DBMET01613 | |
| 0.039 | 0.177 | 0.06 | Phosphodiesterase 1C inhibitor | 0.06 0.047 DBMET02460 | DBMET02460 | |
| 0.009 | 0.148 | 0.056 | Kainate receptor antagonist | 0.056 0.018 DBMET01613 | DBMET01613 | |
| 0.028 | 0.168 | 0.067 | Epithelial sodium channel blocker | 0.067 0.02 DBMET01613 0.064 0.024 DBMET02460 | DBMET01613 | |
| 0.02 | 0.162 | 0.049 | GHS receptor agonist | 0.049 0.021 DBMET02460 | DBMET02460 | |
| 0.076 | 0.22 | 0.16 | Protein kinase (CK1) gamma 3 inhibitor | 0.16 0.079 DBMET01613 | DBMET01613 | |
| 0.026 | 0.171 | 0.061 | Squalene epoxidase inhibitor | 0.061 0.02 DBMET02460 | DBMET02460 | |
| 0.036 | 0.181 | 0.108 | Acetylcholine nicotinic agonist | 0.108 0.032 DBMET01613 | DBMET01613 | |
| 0.066 | 0.212 | 0.128 | Cell adhesion inhibitor | 0.128 0.06 DBMET02461 | DBMET02461 | |
| 0.09 | 0.239 | 0.226 | Interferon gamma antagonist | 0.125 0.122 DBMET01614 0.226 0.033 DBMET02460 | DBMET02460 | |
| 0.077 | 0.227 | 0.119 | Aurora-C kinase inhibitor | 0.119 0.109 DBMET01613 | DBMET01613 | |
| 0.06 | 0.213 | 0.202 | Cytidine deaminase inhibitor | 0.172 0.061 DBMET01613 0.202 0.047 DBMET02460 | DBMET02460 | |
| 0.097 | 0.249 | 0.266 | Neurotrophic factor enhancer | 0.157 0.128 DBMET02464 0.147 0.143 DBMET01613 0.266 0.03 DBMET02460 | DBMET02460 | |
| 0.024 | 0.177 | 0.051 | Glutamate (mGluR group III) antagonist | 0.051 0.019 DBMET02460 | DBMET02460 | |
| 0.011 | 0.164 | 0.049 | Glycine transporter inhibitor | 0.049 0.032 DBMET01613 0.049 0.032 DBMET02460 | DBMET02460 | |
| 0.073 | 0.227 | 0.26 | Phospholipase A2 inhibitor | 0.151 0.073 DBMET01614 0.202 0.042 DBMET02455 0.121 0.116 DBMET02466 0.172 0.058 DBMET02457 0.152 0.072 DBMET02459 0.122 0.113 DBMET02460 0.26 0.021 DBMET02461 | DBMET02461 | |
| 0.057 | 0.212 | 0.111 | Growth factor antagonist | 0.111 0.101 DBMET02463 | DBMET02463 | |
| 0.08 | 0.235 | 0.13 | DNA repair enzyme inhibitor | 0.116 0.08 DBMET01611 0.13 0.054 DBMET02460 | DBMET02460 | |
| 0.028 | 0.186 | 0.095 | CC chemokine receptor antagonist | 0.095 0.038 DBMET01613 | DBMET01613 | |
| 0.005 | 0.163 | 0.014 | Thyroid hormone alpha antagonist | 0.014 0.012 DBMET02460 | DBMET02460 | |
| 0.026 | 0.184 | 0.081 | Protein kinase C beta inhibitor | 0.081 0.029 DBMET01613 | DBMET01613 | |
| 0.052 | 0.21 | 0.08 | Interleukin 5 antagonist | 0.08 0.074 DBMET02460 | DBMET02460 | |
| 0.089 | 0.25 | 0.168 | Pregnane X receptor agonist | 0.154 0.046 DBMET01613 0.168 0.028 DBMET02460 | DBMET02460 | |
| 0.004 | 0.165 | 0.024 | Prostaglandin E2 agonist | 0.024 0.015 DBMET02460 | DBMET02460 | |
| 0.053 | 0.216 | 0.128 | Lipid peroxidase inhibitor | 0.128 0.086 DBMET02464 | DBMET02464 | |
| 0.009 | 0.174 | 0.031 | Myristoyl transferase inhibitor | 0.031 0.012 DBMET01613 | DBMET01613 | |
| 0.059 | 0.225 | 0.195 | Cyclooxygenase 3 inhibitor | 0.134 0.062 DBMET01613 0.195 0.02 DBMET02460 | DBMET02460 | |
| 0.029 | 0.197 | 0.067 | Glucosylceramidase inhibitor | 0.067 0.024 DBMET01613 | DBMET01613 | |
| 0.035 | 0.203 | 0.125 | Glycine receptor antagonist | 0.125 0.016 DBMET01613 0.125 0.015 DBMET02460 | DBMET02460 | |
| 0.009 | 0.18 | 0.027 | Sodium/glucose cotransporter inhibitor | 0.027 0.015 DBMET02460 | DBMET02460 | |
| 0.089 | 0.262 | 0.315 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.182 0.105 DBMET02463 0.315 0.034 DBMET02460 | DBMET02460 | |
| 0.029 | 0.202 | 0.061 | Alpha 1b adrenoreceptor agonist | 0.061 0.018 DBMET01613 | DBMET01613 | |
| 0.018 | 0.19 | 0.072 | Nicotinic neuronal receptor agonist | 0.072 0.026 DBMET01613 | DBMET01613 | |
| 0.033 | 0.206 | 0.076 | Protein kinase B gamma inhibitor | 0.076 0.05 DBMET01613 | DBMET01613 | |
| 0.028 | 0.201 | 0.091 | Sirtuin 1 inhibitor | 0.064 0.053 DBMET02455 0.06 0.059 DBMET02466 0.066 0.05 DBMET02457 0.063 0.054 DBMET02459 0.091 0.028 DBMET02461 | DBMET02461 | |
| 0.024 | 0.197 | 0.061 | Check point kinase 1 inhibitor | 0.061 0.057 DBMET01613 | DBMET01613 | |
| 0.103 | 0.278 | 0.145 | Catenin beta inhibitor | 0.145 0.117 DBMET01613 | DBMET01613 | |
| 0.016 | 0.191 | 0.06 | Histone deacetylase 9 inhibitor | 0.06 0.012 DBMET01614 | DBMET01614 | |
| 0.048 | 0.224 | 0.137 | Histone deacetylase class III inhibitor | 0.137 0.055 DBMET02461 | DBMET02461 | |
| 0.024 | 0.203 | 0.08 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.08 0.05 DBMET01613 | DBMET01613 | |
| 0.076 | 0.256 | 0.166 | Sphingosine 1-phosphate receptor 2 antagonist | 0.121 0.094 DBMET01613 0.166 0.024 DBMET02460 | DBMET02460 | |
| 0.006 | 0.188 | 0.034 | Prostaglandin agonist | 0.034 0.018 DBMET02460 | DBMET02460 | |
| 0.036 | 0.218 | 0.091 | Bcl-xL inhibitor | 0.066 0.026 DBMET02455 0.065 0.028 DBMET02466 0.066 0.025 DBMET02457 0.072 0.018 DBMET02459 0.091 0.008 DBMET02461 | DBMET02461 | |
| 0.018 | 0.201 | 0.058 | Nicotinic receptor alpha7 subunit antagonist | 0.058 0.031 DBMET01613 | DBMET01613 | |
| 0.01 | 0.193 | 0.032 | Acid ceramidase inhibitor | 0.032 0.007 DBMET01613 0.026 0.018 DBMET02460 | DBMET01613 | |
| 0.011 | 0.195 | 0.089 | Dopamine D5 agonist | 0.057 0.013 DBMET01613 0.089 0.005 DBMET02460 | DBMET02460 | |
| 0.022 | 0.205 | 0.113 | Sphingosine 1-phosphate receptor 4 agonist | 0.113 0.019 DBMET02460 | DBMET02460 | |
| 0.083 | 0.267 | 0.195 | Antipruritic | 0.195 0.052 DBMET02460 | DBMET02460 | |
| 0.023 | 0.207 | 0.084 | Toll-Like receptor 7 antagonist | 0.084 0.034 DBMET01613 | DBMET01613 | |
| 0.015 | 0.2 | 0.038 | Melatonin receptor 1A agonist | 0.038 0.016 DBMET01614 | DBMET01614 | |
| 0.038 | 0.223 | 0.122 | Protein kinase C delta inhibitor | 0.122 0.035 DBMET01613 | DBMET01613 | |
| 0.025 | 0.211 | 0.082 | Protein kinase C alpha inhibitor | 0.082 0.033 DBMET01613 | DBMET01613 | |
| 0.058 | 0.245 | 0.185 | Mcl-1 antagonist | 0.185 0.064 DBMET02459 | DBMET02459 | |
| 0.009 | 0.196 | 0.042 | AMPA receptor antagonist | 0.042 0.041 DBMET01613 | DBMET01613 | |
| 0.066 | 0.254 | 0.19 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.19 0.07 DBMET02465 | DBMET02465 | |
| 0.04 | 0.228 | 0.175 | Cholesterol synthesis inhibitor | 0.175 0.034 DBMET02460 | DBMET02460 | |
| 0.015 | 0.204 | 0.045 | AMPA 4 receptor antagonist | 0.045 0.02 DBMET01613 | DBMET01613 | |
| 0.031 | 0.221 | 0.125 | Protein kinase (CK2) alpha inhibitor | 0.12 0.062 DBMET01613 0.125 0.059 DBMET02460 | DBMET02460 | |
| 0.039 | 0.23 | 0.118 | Prolactin inhibitor | 0.118 0.039 DBMET02460 | DBMET02460 | |
| 0.022 | 0.214 | 0.075 | Cyclin-dependent kinase 4 inhibitor | 0.075 0.038 DBMET01613 | DBMET01613 | |
| 0.007 | 0.199 | 0.039 | Free fatty acid receptor 1 antagonist | 0.039 0.017 DBMET02460 | DBMET02460 | |
| 0.049 | 0.241 | 0.188 | ABCA1 expression enhancer | 0.188 0.011 DBMET01614 | DBMET01614 | |
| 0.033 | 0.226 | 0.075 | Adenine nucleotide translocase inhibitor | 0.062 0.024 DBMET02455 0.059 0.031 DBMET02466 0.062 0.026 DBMET02457 0.06 0.029 DBMET02459 0.075 0.012 DBMET02461 | DBMET02461 | |
| 0.012 | 0.206 | 0.05 | Stearoyl-CoA desaturase inhibitor | 0.05 0.023 DBMET01613 | DBMET01613 | |
| 0.005 | 0.199 | 0.029 | Histamine H4 receptor agonist | 0.029 0.007 DBMET01613 | DBMET01613 | |
| 0.012 | 0.207 | 0.031 | Thymidine phosphorylase inhibitor | 0.031 0.011 DBMET01613 0.029 0.013 DBMET02460 | DBMET01613 | |
| 0.092 | 0.287 | 0.395 | Phospholipase C inhibitor | 0.234 0.029 DBMET01613 0.216 0.035 DBMET02455 0.226 0.031 DBMET02466 0.196 0.046 DBMET02457 0.147 0.112 DBMET02459 0.198 0.045 DBMET02460 0.395 0.011 DBMET02461 | DBMET02461 | |
| 0.018 | 0.213 | 0.094 | Adenylate cyclase 1 inhibitor | 0.094 0.005 DBMET02460 | DBMET02460 | |
| 0.007 | 0.202 | 0.032 | AMPA 3 receptor antagonist | 0.032 0.019 DBMET01613 | DBMET01613 | |
| 0.023 | 0.219 | 0.055 | Sphingosine kinase inhibitor | 0.055 0.048 DBMET02460 | DBMET02460 | |
| 0.041 | 0.237 | 0.385 | Tubulin antagonist | 0.385 0.013 DBMET02460 | DBMET02460 | |
| 0.004 | 0.202 | 0.053 | Nicotinic alpha4 receptor agonist | 0.053 0.004 DBMET01613 0.015 0.013 DBMET02460 | DBMET01613 | |
| 0.129 | 0.329 | 0.337 | Apoptosis antagonist | 0.2 0.179 DBMET01614 0.238 0.139 DBMET02455 0.302 0.084 DBMET02466 0.265 0.113 DBMET02457 0.27 0.109 DBMET02459 0.252 0.125 DBMET02460 0.337 0.062 DBMET02461 | DBMET02461 | |
| 0.043 | 0.243 | 0.104 | Bile acid receptor antagonist | 0.104 0.041 DBMET02460 | DBMET02460 | |
| 0.055 | 0.255 | 0.121 | Antibacterial (Helicobacter pylori) | 0.108 0.102 DBMET02455 0.121 0.079 DBMET02460 | DBMET02460 | |
| 0.025 | 0.227 | 0.065 | Bombesin 2 receptor antagonist | 0.046 0.04 DBMET01613 0.045 0.042 DBMET02460 0.065 0.021 DBMET02461 | DBMET02461 | |
| 0.002 | 0.205 | 0.019 | G-protein-coupled receptor 120 agonist | 0.019 0.01 DBMET02460 | DBMET02460 | |
| 0.027 | 0.231 | 0.075 | Protein kinase A inhibitor | 0.075 0.065 DBMET01613 | DBMET01613 | |
| 0.015 | 0.22 | 0.12 | NMDA receptor glycine site agonist | 0.094 0.02 DBMET01613 0.12 0.009 DBMET02460 | DBMET02460 | |
| 0.006 | 0.211 | 0.042 | Estradiol 17 beta-dehydrogenase 3 inhibitor | 0.042 0.014 DBMET02460 | DBMET02460 | |
| 0.018 | 0.224 | 0.044 | Glutamate (mGluR8) antagonist | 0.044 0.012 DBMET02461 | DBMET02461 | |
| 0.052 | 0.259 | 0.092 | Alpha 2d adrenoreceptor antagonist | 0.092 0.067 DBMET01613 | DBMET01613 | |
| 0.016 | 0.222 | 0.064 | CDK4/cyclin D1 inhibitor | 0.064 0.036 DBMET01613 | DBMET01613 | |
| 0.033 | 0.24 | 0.068 | Ryanodine receptor antagonist | 0.068 0.021 DBMET02460 | DBMET02460 | |
| 0.035 | 0.242 | 0.064 | Histone deacetylase SIRT3 inhibitor | 0.064 0.038 DBMET01613 | DBMET01613 | |
| 0.134 | 0.342 | 0.315 | Analgesic | 0.304 0.139 DBMET01613 0.315 0.13 DBMET02456 | DBMET02456 | |
| 0.027 | 0.235 | 0.075 | Heat shock protein 90 beta antagonist | 0.057 0.045 DBMET01613 0.075 0.024 DBMET02460 | DBMET02460 | |
| 0.015 | 0.223 | 0.054 | CC chemokine 2 receptor antagonist | 0.054 0.039 DBMET01613 | DBMET01613 | |
| 0.07 | 0.278 | 0.261 | MAP kinase kinase 2 inhibitor | 0.261 0.049 DBMET01613 0.18 0.096 DBMET02460 | DBMET01613 | |
| 0.105 | 0.314 | 0.184 | Ca2+-transporting ATPase inhibitor | 0.145 0.057 DBMET01613 0.184 0.005 DBMET02460 | DBMET02460 | |
| 0.126 | 0.338 | 0.41 | Tyrosine 3 hydroxylase inhibitor | 0.279 0.045 DBMET01613 0.186 0.162 DBMET01614 0.41 0.007 DBMET02460 0.21 0.119 DBMET02461 | DBMET02460 | |
| 0.041 | 0.253 | 0.117 | GABA B receptor agonist | 0.086 0.031 DBMET01613 0.117 0.008 DBMET02460 | DBMET02460 | |
| 0.021 | 0.234 | 0.061 | Sphingosine kinase 2 inhibitor | 0.061 0.031 DBMET01613 0.061 0.03 DBMET02460 | DBMET02460 | |
| 0.017 | 0.23 | 0.1 | Glucagon-like peptide 1 agonist | 0.074 0.039 DBMET02455 0.077 0.037 DBMET02466 0.071 0.041 DBMET02457 0.061 0.047 DBMET02459 0.1 0.022 DBMET02461 | DBMET02461 | |
| 0.064 | 0.278 | 0.199 | Sphingosine 1-phosphate receptor 4 antagonist | 0.199 0.009 DBMET02460 | DBMET02460 | |
| 0.005 | 0.221 | 0.046 | Imidazoline I1 receptor antagonist | 0.046 0.004 DBMET01613 0.025 0.01 DBMET02460 | DBMET01613 | |
| 0.04 | 0.256 | 0.092 | GABA receptor agonist | 0.092 0.087 DBMET02460 | DBMET02460 | |
| 0.014 | 0.231 | 0.041 | Dihydrofolate reductase inhibitor | 0.041 0.038 DBMET01613 | DBMET01613 | |
| 0.027 | 0.244 | 0.103 | Check point kinase 2 inhibitor | 0.103 0.063 DBMET01613 | DBMET01613 | |
| 0.01 | 0.228 | 0.048 | Glutamate (mGluR5) agonist | 0.048 0.028 DBMET01613 0.047 0.029 DBMET02460 | DBMET01613 | |
| 0.118 | 0.336 | 0.337 | Insulysin inhibitor | 0.236 0.11 DBMET01613 0.211 0.141 DBMET02455 0.228 0.119 DBMET02459 0.274 0.076 DBMET02460 0.337 0.039 DBMET02461 | DBMET02461 | |
| 0.015 | 0.235 | 0.052 | Protein kinase C theta inhibitor | 0.052 0.05 DBMET01613 | DBMET01613 | |
| 0.03 | 0.249 | 0.059 | Interferon inducer | 0.059 0.056 DBMET02460 | DBMET02460 | |
| 0.05 | 0.271 | 0.171 | Activin receptor-like kinase 2 inhibitor | 0.171 0.052 DBMET01613 | DBMET01613 | |
| 0.004 | 0.226 | 0.054 | GP IIb/IIIa receptor antagonist | 0.054 0.03 DBMET02461 | DBMET02461 | |
| 0.011 | 0.234 | 0.051 | Glutamate (mGluR3) antagonist | 0.051 0.012 DBMET02460 | DBMET02460 | |
| 0.043 | 0.266 | 0.294 | Amylase inhibitor | 0.294 0.019 DBMET01614 0.232 0.033 DBMET02460 | DBMET01614 | |
| 0.042 | 0.266 | 0.122 | Bromodomain-containing protein 2 inhibitor | 0.109 0.032 DBMET01613 0.122 0.022 DBMET02460 | DBMET02460 | |
| 0.016 | 0.24 | 0.078 | Benzodiazepine agonist | 0.078 0.041 DBMET02460 | DBMET02460 | |
| 0.054 | 0.278 | 0.091 | CC chemokine 5 receptor agonist | 0.08 0.063 DBMET01613 0.091 0.035 DBMET02460 | DBMET02460 | |
| 0.014 | 0.239 | 0.055 | CDK4/cyclin D inhibitor | 0.055 0.046 DBMET01613 | DBMET01613 | |
| 0.008 | 0.233 | 0.043 | Carbonic anhydrase VII inhibitor | 0.043 0.036 DBMET02460 | DBMET02460 | |
| 0.015 | 0.243 | 0.066 | EphB4 antagonist | 0.066 0.033 DBMET01613 | DBMET01613 | |
| 0.071 | 0.301 | 0.192 | Adenylate cyclase stimulant | 0.136 0.089 DBMET01613 0.192 0.018 DBMET02460 | DBMET02460 | |
| 0.041 | 0.271 | 0.152 | MAP kinase kinase 1 inhibitor | 0.095 0.064 DBMET01613 0.152 0.016 DBMET02460 | DBMET02460 | |
| 0.016 | 0.249 | 0.043 | Neurokinin 2 agonist | 0.043 0.026 DBMET02461 | DBMET02461 | |
| 0.021 | 0.253 | 0.073 | Nav1.8 sodium channel blocker | 0.073 0.052 DBMET01611 | DBMET01611 | |
| 0.037 | 0.271 | 0.135 | Alkylator | 0.112 0.076 DBMET01614 0.135 0.055 DBMET02460 0.099 0.089 DBMET02461 | DBMET02460 | |
| 0.001 | 0.236 | 0.012 | Thromboxane agonist | 0.012 0.007 DBMET02460 | DBMET02460 | |
| 0.036 | 0.271 | 0.126 | Aminoacyl-tRNA synthetase inhibitor | 0.086 0.066 DBMET02455 0.083 0.07 DBMET02466 0.084 0.069 DBMET02457 0.126 0.027 DBMET02461 | DBMET02461 | |
| 0.054 | 0.292 | 0.143 | Interleukin 8 antagonist | 0.143 0.039 DBMET01613 0.14 0.041 DBMET02460 | DBMET01613 | |
| 0.022 | 0.26 | 0.115 | Protein kinase (CK2) inhibitor | 0.115 0.051 DBMET01613 0.109 0.056 DBMET02460 | DBMET01613 | |
| 0.01 | 0.248 | 0.045 | Integrin alpha5beta1 antagonist | 0.037 0.035 DBMET02466 0.045 0.023 DBMET02461 | DBMET02461 | |
| 0.007 | 0.246 | 0.026 | Calcium-sensing receptor agonist | 0.026 0.019 DBMET01613 | DBMET01613 | |
| 0.014 | 0.253 | 0.053 | Prolyl endopeptidase inhibitor | 0.053 0.032 DBMET02460 | DBMET02460 | |
| 0.008 | 0.252 | 0.059 | Glutamate (mGluR1) antagonist | 0.059 0.04 DBMET01613 | DBMET01613 | |
| 0.025 | 0.271 | 0.064 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.064 0.036 DBMET01613 0.059 0.045 DBMET02460 | DBMET01613 | |
| 0.014 | 0.262 | 0.055 | Benzodiazepine antagonist | 0.055 0.019 DBMET02460 | DBMET02460 | |
| 0.009 | 0.262 | 0.045 | Glutamate (mGluR group I) agonist | 0.045 0.037 DBMET01613 0.045 0.037 DBMET02460 | DBMET02460 | |
| 0.006 | 0.262 | 0.114 | Potassium channel small-conductance Ca-activated activator | 0.114 0.004 DBMET01613 0.043 0.013 DBMET02460 | DBMET01613 | |
| 0.056 | 0.314 | 0.183 | I kappa B kinase epsilon inhibitor | 0.183 0.086 DBMET01613 0.176 0.093 DBMET02460 | DBMET01613 | |
| 0.018 | 0.276 | 0.052 | Vanilloid 3 antagonist | 0.052 0.007 DBMET02460 | DBMET02460 | |
| 0.048 | 0.308 | 0.114 | Hedgehog signaling inhibitor | 0.114 0.045 DBMET01613 | DBMET01613 | |
| 0.029 | 0.289 | 0.08 | Potassium channel large-conductance Ca-activated activator | 0.08 0.035 DBMET02460 | DBMET02460 | |
| 0.051 | 0.311 | 0.08 | Transforming growth factor beta 3 antagonist | 0.08 0.065 DBMET01613 | DBMET01613 | |
| 0.04 | 0.301 | 0.263 | Electrolyte absorption antagonist | 0.14 0.023 DBMET01613 0.263 0.004 DBMET02460 | DBMET02460 | |
| 0.054 | 0.315 | 0.231 | Insulin sensitizer | 0.151 0.132 DBMET02455 0.151 0.132 DBMET02457 0.18 0.095 DBMET02460 0.231 0.046 DBMET02461 | DBMET02461 | |
| 0.031 | 0.294 | 0.136 | Protein kinase C mu inhibitor | 0.136 0.033 DBMET01613 | DBMET01613 | |
| 0.014 | 0.278 | 0.032 | Elastase 3B inhibitor | 0.032 0.018 DBMET02460 | DBMET02460 | |
| 0.014 | 0.278 | 0.032 | Elastase 3A inhibitor | 0.032 0.018 DBMET02460 | DBMET02460 | |
| 0.014 | 0.278 | 0.032 | Elastase 2B inhibitor | 0.032 0.018 DBMET02460 | DBMET02460 | |
| 0.004 | 0.268 | 0.041 | Uridine phosphorylase inhibitor | 0.041 0.011 DBMET02460 | DBMET02460 | |
| 0.008 | 0.275 | 0.105 | Aromatase inhibitor | 0.105 0.02 DBMET02460 | DBMET02460 | |
| 0.003 | 0.273 | 0.019 | Complement factor D inhibitor | 0.019 0.011 DBMET02460 | DBMET02460 | |
| 0.05 | 0.319 | 0.215 | Diuretic | 0.215 0.039 DBMET02460 0.188 0.049 DBMET02461 | DBMET02460 | |
| 0.13 | 0.4 | 0.377 | Apoptosis agonist | 0.239 0.226 DBMET02464 0.252 0.212 DBMET02455 0.343 0.143 DBMET02466 0.242 0.224 DBMET02457 0.377 0.125 DBMET02459 0.35 0.138 DBMET02461 | DBMET02459 | |
| 0.012 | 0.283 | 0.051 | Histamine H1 receptor agonist | 0.051 0.017 DBMET01613 0.048 0.021 DBMET02460 | DBMET01613 | |
| 0.033 | 0.305 | 0.145 | Chelator | 0.097 0.082 DBMET02455 0.099 0.078 DBMET02466 0.109 0.065 DBMET02457 0.105 0.071 DBMET02459 0.145 0.037 DBMET02461 | DBMET02461 | |
| 0.006 | 0.279 | 0.02 | Alpha 2d adrenoreceptor agonist | 0.02 0.018 DBMET01613 | DBMET01613 | |
| 0.004 | 0.278 | 0.044 | Nicotinic alpha4beta2 receptor agonist | 0.044 0.006 DBMET01613 0.032 0.014 DBMET02460 | DBMET01613 | |
| 0.05 | 0.324 | 0.091 | T cell inhibitor | 0.091 0.036 DBMET02460 | DBMET02460 | |
| 0.007 | 0.285 | 0.073 | Nicotinic acid receptor 2 agonist | 0.073 0.009 DBMET02460 | DBMET02460 | |
| 0.053 | 0.331 | 0.518 | Interleukin antagonist | 0.282 0.052 DBMET02455 0.256 0.059 DBMET02466 0.284 0.051 DBMET02457 0.332 0.041 DBMET02459 0.216 0.076 DBMET02460 0.518 0.018 DBMET02461 | DBMET02461 | |
| 0.039 | 0.318 | 0.139 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.139 0.13 DBMET02456 | DBMET02456 | |
| 0.003 | 0.284 | 0.031 | Prostaglandin EP2 agonist | 0.031 0.012 DBMET02460 | DBMET02460 | |
| 0.026 | 0.312 | 0.091 | Myeloperoxidase inhibitor | 0.091 0.047 DBMET02460 | DBMET02460 | |
| 0.026 | 0.313 | 0.15 | Urease inhibitor | 0.15 0.023 DBMET02460 | DBMET02460 | |
| 0.021 | 0.308 | 0.096 | Potassium channel intermediate-conductance Ca-activated blocker | 0.096 0.01 DBMET02460 | DBMET02460 | |
| 0.035 | 0.324 | 0.122 | Sodium channel blocker | 0.122 0.082 DBMET01613 | DBMET01613 | |
| 0.044 | 0.333 | 0.136 | Photosensitizer | 0.108 0.074 DBMET01614 0.136 0.041 DBMET02460 | DBMET02460 | |
| 0.012 | 0.302 | 0.064 | Erythropoietin receptor agonist | 0.035 0.034 DBMET02455 0.036 0.032 DBMET02457 0.064 0.016 DBMET02461 | DBMET02461 | |
| 0.022 | 0.313 | 0.092 | Pregnane X receptor antagonist | 0.053 0.05 DBMET01613 0.092 0.004 DBMET02460 | DBMET02460 | |
| 0.013 | 0.304 | 0.032 | Vanilloid 4 antagonist | 0.032 0.023 DBMET01613 | DBMET01613 | |
| 0.023 | 0.315 | 0.131 | Pim-3 kinase inhibitor | 0.131 0.025 DBMET01613 | DBMET01613 | |
| 0.128 | 0.421 | 0.247 | MAP kinase 1 inhibitor | 0.247 0.237 DBMET02460 | DBMET02460 | |
| 0.019 | 0.313 | 0.079 | Metalloproteinase-9 inhibitor | 0.079 0.045 DBMET02461 | DBMET02461 | |
| 0.026 | 0.32 | 0.078 | Somatostatin 1 agonist | 0.071 0.063 DBMET02466 0.078 0.054 DBMET02461 | DBMET02461 | |
| 0.032 | 0.327 | 0.119 | Lipocortins synthesis agonist | 0.056 0.044 DBMET02458 0.119 0.003 DBMET02460 0.06 0.035 DBMET02461 | DBMET02460 | |
| 0.038 | 0.333 | 0.097 | Phosphodiesterase 7B inhibitor | 0.097 0.06 DBMET01613 | DBMET01613 | |
| 0.015 | 0.313 | 0.047 | Neuropeptide agonist | 0.047 0.044 DBMET02461 | DBMET02461 | |
| 0.064 | 0.362 | 0.143 | MAP kinase 3 inhibitor | 0.129 0.11 DBMET01613 0.143 0.079 DBMET02460 | DBMET02460 | |
| 0.039 | 0.338 | 0.129 | Adenylate cyclase inhibitor | 0.129 0.061 DBMET02460 | DBMET02460 | |
| 0.023 | 0.322 | 0.153 | Potassium channel (Ca-activated) activator | 0.124 0.039 DBMET01613 0.153 0.027 DBMET02460 | DBMET02460 | |
| 0.043 | 0.344 | 0.157 | Protein kinase stimulant | 0.157 0.063 DBMET02460 | DBMET02460 | |
| 0.046 | 0.348 | 0.112 | Estrogen-related receptor beta agonist | 0.112 0.014 DBMET02460 | DBMET02460 | |
| 0.098 | 0.402 | 0.163 | Heat shock protein 70 antagonist | 0.137 0.085 DBMET01613 0.163 0.024 DBMET02460 | DBMET02460 | |
| 0.002 | 0.306 | 0.013 | Carbonic anhydrase XI inhibitor | 0.013 0.009 DBMET02460 | DBMET02460 | |
| 0.017 | 0.322 | 0.079 | CDC25A inhibitor | 0.079 0.044 DBMET02460 0.072 0.054 DBMET02461 | DBMET02460 | |
| 0.019 | 0.323 | 0.117 | NMDA receptor agonist | 0.073 0.034 DBMET01613 0.114 0.015 DBMET02460 0.117 0.014 DBMET02461 | DBMET02461 | |
| 0.007 | 0.314 | 0.029 | Thyroid hormone agonist | 0.029 0.013 DBMET02460 | DBMET02460 | |
| 0.029 | 0.337 | 0.063 | Caspase 9 inhibitor | 0.063 0.042 DBMET01614 0.06 0.047 DBMET02461 | DBMET01614 | |
| 0.032 | 0.341 | 0.19 | GABA C receptor rho-1 antagonist | 0.157 0.018 DBMET01613 0.19 0.01 DBMET02460 | DBMET02460 | |
| 0.016 | 0.327 | 0.066 | Nitric oxide donor | 0.066 0.038 DBMET02461 | DBMET02461 | |
| 0.008 | 0.319 | 0.034 | Histone deacetylase 7 inhibitor | 0.034 0.028 DBMET01614 | DBMET01614 | |
| 0.017 | 0.328 | 0.119 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.119 0.029 DBMET02460 | DBMET02460 | |
| 0.004 | 0.316 | 0.036 | Corticosteroid-like | 0.036 0.005 DBMET02460 | DBMET02460 | |
| 0.004 | 0.322 | 0.048 | Farnesoid X receptor agonist | 0.048 0.016 DBMET02460 | DBMET02460 | |
| 0.049 | 0.368 | 0.208 | Nitric oxide antagonist | 0.208 0.064 DBMET02460 | DBMET02460 | |
| 0.006 | 0.325 | 0.028 | LFA antagonist | 0.028 0.019 DBMET02460 | DBMET02460 | |
| 0.035 | 0.355 | 0.091 | MAP kinase kinase 7 inhibitor | 0.088 0.027 DBMET01613 0.091 0.023 DBMET02460 | DBMET02460 | |
| 0.053 | 0.373 | 0.44 | Prostaglandin dehydrogenase inhibitor | 0.44 0.056 DBMET02460 | DBMET02460 | |
| 0.017 | 0.338 | 0.107 | Metalloproteinase-2 inhibitor | 0.107 0.035 DBMET02461 | DBMET02461 | |
| 0.073 | 0.395 | 0.49 | Immunosuppressant | 0.234 0.163 DBMET02466 0.49 0.036 DBMET02460 0.318 0.104 DBMET02461 | DBMET02460 | |
| 0.011 | 0.334 | 0.053 | Adenosine deaminase inhibitor | 0.053 0.027 DBMET02460 | DBMET02460 | |
| 0.013 | 0.338 | 0.183 | Catalase inhibitor | 0.183 0.019 DBMET01614 0.126 0.032 DBMET02460 0.181 0.019 DBMET02461 | DBMET01614 | |
| 0.028 | 0.355 | 0.138 | Sodium channel (voltage-gated) blocker | 0.138 0.064 DBMET01613 0.118 0.086 DBMET02460 | DBMET01613 | |
| 0.047 | 0.374 | 0.386 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.386 0.041 DBMET02460 | DBMET02460 | |
| 0.004 | 0.331 | 0.045 | Nicotinic alpha3beta4 receptor agonist | 0.045 0.007 DBMET01613 0.038 0.012 DBMET02460 | DBMET01613 | |
| 0.008 | 0.338 | 0.092 | Neutrophil collagenase inhibitor | 0.092 0.025 DBMET02461 | DBMET02461 | |
| 0.046 | 0.376 | 0.304 | Amyloid beta precursor protein antagonist | 0.304 0.016 DBMET02460 | DBMET02460 | |
| 0.044 | 0.374 | 0.522 | Immunostimulant | 0.177 0.135 DBMET01614 0.269 0.089 DBMET02455 0.396 0.051 DBMET02466 0.309 0.076 DBMET02457 0.377 0.056 DBMET02459 0.22 0.109 DBMET02460 0.522 0.026 DBMET02461 | DBMET02461 | |
| 0.004 | 0.335 | 0.048 | Methionyl aminopeptidase 1 inhibitor | 0.048 0.007 DBMET01613 0.034 0.018 DBMET02460 | DBMET01613 | |
| 0.05 | 0.381 | 0.138 | Folate antagonist | 0.099 0.066 DBMET02455 0.091 0.085 DBMET02466 0.097 0.071 DBMET02457 0.138 0.027 DBMET02461 | DBMET02461 | |
| 0.004 | 0.337 | 0.036 | Calpain 1 inhibitor | 0.036 0.017 DBMET01614 | DBMET01614 | |
| 0.024 | 0.357 | 0.141 | MAP kinase kinase inhibitor | 0.141 0.057 DBMET02460 | DBMET02460 | |
| 0.07 | 0.404 | 0.275 | DNA synthesis inhibitor | 0.248 0.068 DBMET01613 0.192 0.136 DBMET01614 0.275 0.053 DBMET02460 | DBMET02460 | |
| 0.059 | 0.396 | 0.312 | Growth hormone agonist | 0.153 0.085 DBMET02455 0.177 0.069 DBMET02466 0.158 0.081 DBMET02457 0.173 0.071 DBMET02459 0.312 0.03 DBMET02461 | DBMET02461 | |
| 0.017 | 0.358 | 0.195 | Pim-1 kinase inhibitor | 0.096 0.062 DBMET01613 0.195 0.015 DBMET02456 | DBMET02456 | |
| 0.055 | 0.397 | 0.375 | Succinate dehydrogenase inhibitor | 0.178 0.07 DBMET01613 0.188 0.06 DBMET01614 0.375 0.005 DBMET02460 | DBMET02460 | |
| 0.05 | 0.393 | 0.208 | Calpain inhibitor | 0.183 0.131 DBMET01614 0.208 0.106 DBMET02460 0.191 0.122 DBMET02461 | DBMET02460 | |
| 0.026 | 0.371 | 0.106 | Glycine receptor agonist | 0.071 0.052 DBMET01613 0.106 0.018 DBMET02460 | DBMET02460 | |
| 0.057 | 0.404 | 0.533 | Thioredoxin glutathione reductase inhibitor | 0.533 0.023 DBMET02460 | DBMET02460 | |
| 0.002 | 0.35 | 0.057 | Arginase inhibitor | 0.036 0.025 DBMET02460 0.057 0.011 DBMET02461 | DBMET02461 | |
| 0.099 | 0.447 | 0.332 | Nitric-oxide synthase stimulant | 0.222 0.058 DBMET01613 0.332 0.006 DBMET02460 | DBMET02460 | |
| 0.004 | 0.352 | 0.037 | Kynurenine 3 monooxygenase inhibitor | 0.037 0.011 DBMET02460 | DBMET02460 | |
| 0.009 | 0.357 | 0.046 | Mannosidase inhibitor | 0.046 0.03 DBMET02460 | DBMET02460 | |
| 0.025 | 0.374 | 0.219 | GABA C receptor antagonist | 0.173 0.02 DBMET01613 0.219 0.009 DBMET02460 | DBMET02460 | |
| 0.036 | 0.386 | 0.105 | Calcium channel N-type blocker | 0.105 0.087 DBMET02460 | DBMET02460 | |
| 0.045 | 0.394 | 0.101 | CDK3/cyclin E inhibitor | 0.101 0.085 DBMET01613 | DBMET01613 | |
| 0.005 | 0.355 | 0.453 | Beta tubulin antagonist | 0.453 0.004 DBMET02460 0.085 0.027 DBMET02461 | DBMET02460 | |
| 0.035 | 0.386 | 0.215 | Anticoagulant | 0.138 0.092 DBMET02455 0.152 0.078 DBMET02466 0.132 0.098 DBMET02457 0.137 0.092 DBMET02459 0.215 0.048 DBMET02461 | DBMET02461 | |
| 0.014 | 0.366 | 0.053 | Sphingosine 1-phosphate receptor 3 antagonist | 0.053 0.051 DBMET02460 | DBMET02460 | |
| 0.018 | 0.37 | 0.063 | Cyclin H inhibitor | 0.063 0.035 DBMET01613 | DBMET01613 | |
| 0.01 | 0.363 | 0.063 | Pim-2 kinase inhibitor | 0.063 0.028 DBMET01613 | DBMET01613 | |
| 0.042 | 0.395 | 0.158 | Cyclin-dependent kinase 8 inhibitor | 0.158 0.072 DBMET01613 | DBMET01613 | |
| 0.005 | 0.36 | 0.044 | 5 Hydroxytryptamine 6 agonist | 0.044 0.006 DBMET01613 | DBMET01613 | |
| 0.001 | 0.361 | 0.008 | DNA topoisomerase III inhibitor | 0.008 0.005 DBMET02460 | DBMET02460 | |
| 0.01 | 0.371 | 0.062 | Lysophosphatidic acid 3 receptor antagonist | 0.056 0.028 DBMET02460 0.062 0.02 DBMET02461 | DBMET02461 | |
| 0.004 | 0.365 | 0.044 | Phosphoglycerate kinase inhibitor | 0.044 0.017 DBMET02460 | DBMET02460 | |
| 0.039 | 0.401 | 0.14 | TRPA1 agonist | 0.131 0.046 DBMET01614 0.14 0.039 DBMET02460 | DBMET02460 | |
| 0.01 | 0.372 | 0.076 | Matrix metalloproteinase inhibitor | 0.076 0.039 DBMET02461 | DBMET02461 | |
| 0.035 | 0.397 | 0.204 | Toll-Like receptor 2 antagonist | 0.163 0.044 DBMET02460 0.204 0.022 DBMET02461 | DBMET02461 | |
| 0.023 | 0.386 | 0.35 | Cystathionine beta-synthase inhibitor | 0.139 0.046 DBMET01613 0.35 0.006 DBMET02460 | DBMET02460 | |
| 0.053 | 0.416 | 0.294 | 3C-like protease (Human coronavirus) inhibitor | 0.209 0.047 DBMET01613 0.294 0.013 DBMET02460 | DBMET02460 | |
| 0.026 | 0.389 | 0.167 | Anabolic | 0.167 0.011 DBMET02460 0.111 0.048 DBMET02461 | DBMET02460 | |
| 0.049 | 0.413 | 0.257 | Streptokinase A inhibitor | 0.257 0.099 DBMET02460 | DBMET02460 | |
| 0.011 | 0.375 | 0.058 | Alpha-mannosidase inhibitor | 0.058 0.029 DBMET02460 | DBMET02460 | |
| 0.032 | 0.397 | 0.159 | Carbonic anhydrase III inhibitor | 0.159 0.025 DBMET02460 | DBMET02460 | |
| 0.008 | 0.373 | 0.064 | Prostaglandin-E synthase inhibitor | 0.064 0.057 DBMET02460 | DBMET02460 | |
| 0.001 | 0.366 | 0.01 | Progesterone receptor A antagonist | 0.01 0.006 DBMET02460 | DBMET02460 | |
| 0.006 | 0.372 | 0.046 | Potassium channel Kv1.3 blocker | 0.046 0.033 DBMET02460 | DBMET02460 | |
| 0.025 | 0.39 | 0.336 | UDP-glucose 4-epimerase inhibitor | 0.12 0.043 DBMET01613 0.118 0.044 DBMET01614 0.336 0.009 DBMET02460 | DBMET02460 | |
| 0.018 | 0.386 | 0.084 | Cathepsin G inhibitor | 0.084 0.041 DBMET02460 | DBMET02460 | |
| 0.057 | 0.431 | 0.135 | Vanilloid 1 agonist | 0.135 0.057 DBMET02460 0.129 0.067 DBMET02461 | DBMET02460 | |
| 0.005 | 0.38 | 0.031 | Cholesterol ester transfer protein antagonist | 0.031 0.022 DBMET02460 | DBMET02460 | |
| 0.022 | 0.397 | 0.083 | Sphingosine 1-phosphate receptor antagonist | 0.083 0.041 DBMET02460 | DBMET02460 | |
| 0.005 | 0.381 | 0.039 | Integrin antagonist | 0.039 0.031 DBMET02461 | DBMET02461 | |
| 0.017 | 0.393 | 0.056 | CF transmembrane conductance regulator antagonist | 0.044 0.015 DBMET01613 0.056 0.005 DBMET02460 | DBMET02460 | |
| 0.017 | 0.393 | 0.106 | Carbonic anhydrase XIII inhibitor | 0.106 0.035 DBMET02460 | DBMET02460 | |
| 0.002 | 0.379 | 0.025 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.025 0.022 DBMET02460 | DBMET02460 | |
| 0.01 | 0.387 | 0.136 | Carbamoyl phosphate synthetase inhibitor | 0.136 0.013 DBMET02460 0.068 0.036 DBMET02461 | DBMET02460 | |
| 0.006 | 0.384 | 0.049 | ATP citrate lysase inhibitor | 0.049 0.008 DBMET02460 | DBMET02460 | |
| 0.041 | 0.42 | 0.18 | Free radical scavenger | 0.155 0.139 DBMET02464 0.18 0.114 DBMET02461 | DBMET02461 | |
| 0.059 | 0.441 | 0.298 | Transcription factor NF kappa B inhibitor | 0.237 0.137 DBMET01614 0.291 0.099 DBMET02460 0.298 0.095 DBMET02461 | DBMET02461 | |
| 0.01 | 0.393 | 0.057 | GABA B receptor antagonist | 0.041 0.033 DBMET01613 0.057 0.014 DBMET02460 | DBMET02460 | |
| 0.012 | 0.395 | 0.319 | CDC25B inhibitor | 0.319 0.004 DBMET02460 0.093 0.019 DBMET02461 | DBMET02460 | |
| 0.033 | 0.417 | 0.377 | Angiogenesis stimulant | 0.26 0.065 DBMET02455 0.291 0.053 DBMET02466 0.268 0.062 DBMET02457 0.272 0.06 DBMET02459 0.377 0.026 DBMET02461 | DBMET02461 | |
| 0.016 | 0.402 | 0.095 | Aryl hydrocarbon receptor antagonist | 0.069 0.038 DBMET01613 0.095 0.016 DBMET02460 | DBMET02460 | |
| 0.002 | 0.388 | 0.022 | Thromboxane A2 agonist | 0.022 0.005 DBMET02460 | DBMET02460 | |
| 0.011 | 0.397 | 0.07 | Angiotensin-converting enzyme inhibitor | 0.07 0.019 DBMET02461 | DBMET02461 | |
| 0.064 | 0.45 | 0.344 | 15-Lipoxygenase inhibitor | 0.344 0.103 DBMET02460 | DBMET02460 | |
| 0.004 | 0.391 | 0.043 | Dihydropteroate synthase inhibitor | 0.043 0.023 DBMET02460 | DBMET02460 | |
| 0.014 | 0.4 | 0.046 | Neurotensin receptor antagonist | 0.046 0.031 DBMET02461 | DBMET02461 | |
| 0.051 | 0.44 | 0.316 | Lipoxygenase inhibitor | 0.18 0.164 DBMET01614 0.316 0.064 DBMET02460 | DBMET02460 | |
| 0.025 | 0.414 | 0.128 | Caspase 3 inhibitor | 0.124 0.055 DBMET01614 0.12 0.06 DBMET02460 0.128 0.049 DBMET02461 | DBMET02461 | |
| 0.005 | 0.397 | 0.03 | Prostaglandin F2 alpha agonist | 0.03 0.009 DBMET02460 | DBMET02460 | |
| 0.044 | 0.436 | 0.199 | Hexokinase inhibitor | 0.166 0.061 DBMET01613 0.199 0.036 DBMET02460 | DBMET02460 | |
| 0.009 | 0.401 | 0.068 | Cyclin A1 inhibitor | 0.068 0.025 DBMET01613 | DBMET01613 | |
| 0.023 | 0.419 | 0.531 | Glutathione S-transferase inhibitor | 0.153 0.011 DBMET02455 0.108 0.03 DBMET02466 0.155 0.011 DBMET02457 0.178 0.007 DBMET02459 0.148 0.012 DBMET02460 0.531 0.001 DBMET02461 | DBMET02461 | |
| 0.075 | 0.471 | 0.318 | RNA-directed DNA polymerase inhibitor | 0.194 0.108 DBMET01613 0.318 0.028 DBMET02460 | DBMET02460 | |
| 0.045 | 0.441 | 0.189 | Antioxidant | 0.189 0.123 DBMET02461 | DBMET02461 | |
| 0.028 | 0.425 | 0.3 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.122 0.038 DBMET01613 0.3 0.006 DBMET02460 0.174 0.021 DBMET02461 | DBMET02460 | |
| 0.004 | 0.402 | 0.03 | Sodium/glucose cotransporter 2 inhibitor | 0.03 0.013 DBMET02460 | DBMET02460 | |
| 0.025 | 0.425 | 0.106 | Glutamate (mGluR6) antagonist | 0.106 0.009 DBMET02460 0.063 0.056 DBMET02461 | DBMET02460 | |
| 0.008 | 0.409 | 0.08 | Cyclin-dependent kinase 6 inhibitor | 0.08 0.022 DBMET01613 | DBMET01613 | |
| 0.036 | 0.439 | 0.14 | D-Ala-D-Ala ligase inhibitor | 0.096 0.034 DBMET01613 0.14 0.007 DBMET02460 | DBMET02460 | |
| 0.002 | 0.408 | 0.019 | 1-Deoxy-D-xylulose-5-phosphate reductoisomerase inhibitor | 0.019 0.004 DBMET02460 | DBMET02460 | |
| 0.024 | 0.431 | 0.111 | Cyclin-dependent kinase 7 inhibitor | 0.111 0.092 DBMET01613 | DBMET01613 | |
| 0.022 | 0.431 | 0.11 | Interleukin 1 beta converting enzyme inhibitor | 0.11 0.045 DBMET01614 0.088 0.076 DBMET02460 | DBMET01614 | |
| 0.01 | 0.42 | 0.038 | Tryptophan 5 hydroxylase inhibitor | 0.036 0.023 DBMET01613 0.038 0.018 DBMET02460 | DBMET02460 | |
| 0.016 | 0.426 | 0.071 | Protease 3C (Human rhinovirus) inhibitor | 0.062 0.049 DBMET01614 0.071 0.035 DBMET02460 0.068 0.039 DBMET02461 | DBMET02460 | |
| 0.023 | 0.434 | 0.288 | Aryl hydrocarbon receptor agonist | 0.288 0.065 DBMET02460 | DBMET02460 | |
| 0.03 | 0.445 | 0.098 | mTOR complex 2 inhibitor | 0.098 0.036 DBMET02460 | DBMET02460 | |
| 0.005 | 0.422 | 0.029 | Epoxide hydrolase 1 inhibitor | 0.029 0.024 DBMET02460 | DBMET02460 | |
| 0.014 | 0.432 | 0.067 | Thrombin inhibitor | 0.067 0.059 DBMET02461 | DBMET02461 | |
| 0.022 | 0.444 | 0.12 | Carbonic anhydrase VI inhibitor | 0.12 0.029 DBMET02460 | DBMET02460 | |
| 0.007 | 0.429 | 0.046 | Oxytocin agonist | 0.046 0.026 DBMET02460 | DBMET02460 | |
| 0.081 | 0.503 | 0.51 | Caspase 3 stimulant | 0.51 0.019 DBMET02460 0.219 0.144 DBMET02461 | DBMET02460 | |
| 0.031 | 0.454 | 0.192 | Heat shock protein 90 antagonist | 0.192 0.042 DBMET02460 | DBMET02460 | |
| 0.003 | 0.429 | 0.029 | Endothelin B receptor antagonist | 0.029 0.009 DBMET01614 | DBMET01614 | |
| 0.002 | 0.428 | 0.021 | Cyclin T1 inhibitor | 0.021 0.01 DBMET01613 0.021 0.01 DBMET02460 | DBMET02460 | |
| 0.013 | 0.44 | 0.077 | Aminopeptidase microsomal inhibitor | 0.077 0.026 DBMET02461 | DBMET02461 | |
| 0.015 | 0.443 | 0.069 | Topoisomerase II alpha inhibitor | 0.069 0.062 DBMET02461 | DBMET02461 | |
| 0.029 | 0.458 | 0.121 | Nav1.4 sodium channel blocker | 0.121 0.051 DBMET02466 0.116 0.056 DBMET02461 | DBMET02466 | |
| 0.011 | 0.441 | 0.374 | Leukotriene synthesis inhibitor | 0.374 0.004 DBMET02460 | DBMET02460 | |
| 0.005 | 0.435 | 0.049 | Collagenase inhibitor | 0.049 0.035 DBMET02461 | DBMET02461 | |
| 0.005 | 0.436 | 0.029 | Peptide deformylase inhibitor | 0.029 0.022 DBMET02460 0.027 0.026 DBMET02461 | DBMET02460 | |
| 0.019 | 0.452 | 0.058 | CD45 antagonist | 0.058 0.023 DBMET02460 0.053 0.03 DBMET02461 | DBMET02460 | |
| 0.012 | 0.447 | 0.055 | Kainate receptor agonist | 0.055 0.009 DBMET02460 | DBMET02460 | |
| 0.032 | 0.467 | 0.119 | Activin receptor-like kinase 4 inhibitor | 0.119 0.053 DBMET01613 | DBMET01613 | |
| 0.023 | 0.461 | 0.326 | Thrombolytic | 0.188 0.058 DBMET02455 0.209 0.048 DBMET02466 0.189 0.058 DBMET02457 0.196 0.054 DBMET02459 0.326 0.02 DBMET02461 | DBMET02461 | |
| 0.029 | 0.468 | 0.12 | Granulocyte macrophage colony stimulating factor agonist | 0.082 0.069 DBMET01614 0.12 0.016 DBMET02460 | DBMET02460 | |
| 0.012 | 0.452 | 0.043 | Glutamate (mGluR group III) agonist | 0.043 0.029 DBMET02460 | DBMET02460 | |
| 0.043 | 0.483 | 0.434 | 12-Lipoxygenase inhibitor | 0.434 0.031 DBMET02460 | DBMET02460 | |
| 0.024 | 0.465 | 0.296 | Pyruvate kinase inhibitor | 0.296 0.049 DBMET02460 | DBMET02460 | |
| 0.038 | 0.479 | 0.11 | 3C-Like protease (SARS coronavirus) inhibitor | 0.11 0.025 DBMET01614 | DBMET01614 | |
| 0.001 | 0.444 | 0.013 | N-Acetylated alpha-linked acidic dipeptidase inhibitor | 0.013 0.012 DBMET02461 | DBMET02461 | |
| 0.037 | 0.481 | 0.191 | Non-steroidal antiinflammatory agent | 0.191 0.078 DBMET02460 | DBMET02460 | |
| 0.047 | 0.492 | 0.204 | CF transmembrane conductance regulator agonist | 0.135 0.106 DBMET01613 0.204 0.019 DBMET02460 | DBMET02460 | |
| 0.004 | 0.451 | 0.078 | Carbonic anhydrase VB inhibitor | 0.078 0.023 DBMET02460 | DBMET02460 | |
| 0.031 | 0.478 | 0.199 | Carbonic anhydrase XV inhibitor | 0.199 0.019 DBMET02460 | DBMET02460 | |
| 0.033 | 0.482 | 0.717 | Peroxidase inhibitor | 0.174 0.067 DBMET01613 0.549 0.006 DBMET02460 0.717 0.003 DBMET02461 | DBMET02461 | |
| 0.006 | 0.457 | 0.145 | Toll-Like receptor 2 agonist | 0.145 0.011 DBMET02461 | DBMET02461 | |
| 0.016 | 0.467 | 0.142 | LIM domain kinase 1 inhibitor | 0.142 0.106 DBMET01613 | DBMET01613 | |
| 0.04 | 0.491 | 0.147 | Transcription factor STAT6 inhibitor | 0.147 0.026 DBMET01613 0.132 0.042 DBMET02460 | DBMET01613 | |
| 0.027 | 0.479 | 0.262 | NADH dehydrogenase inhibitor | 0.113 0.033 DBMET01613 0.262 0.007 DBMET02460 | DBMET02460 | |
| 0.016 | 0.468 | 0.099 | Potassium channel activator | 0.087 0.065 DBMET01613 0.099 0.049 DBMET02460 | DBMET02460 | |
| 0.003 | 0.455 | 0.025 | Isoleucine-tRNA ligase inhibitor | 0.025 0.011 DBMET02460 | DBMET02460 | |
| 0.004 | 0.46 | 0.022 | Alpha 2b adrenoreceptor agonist | 0.022 0.008 DBMET01613 0.02 0.01 DBMET02460 | DBMET01613 | |
| 0.008 | 0.465 | 0.057 | Aminopeptidase N inhibitor | 0.057 0.026 DBMET02461 | DBMET02461 | |
| 0.05 | 0.508 | 0.246 | Hypoxia-inducible factor 1 alpha inhibitor | 0.209 0.141 DBMET01613 0.246 0.104 DBMET02460 | DBMET02460 | |
| 0.008 | 0.466 | 0.043 | Protein kinase (CK2) beta inhibitor | 0.043 0.01 DBMET01613 0.038 0.014 DBMET02460 | DBMET01613 | |
| 0.048 | 0.507 | 0.182 | Factor V inhibitor | 0.182 0.008 DBMET01614 0.112 0.049 DBMET02455 0.11 0.05 DBMET02466 0.109 0.052 DBMET02457 0.107 0.056 DBMET02459 0.146 0.02 DBMET02461 | DBMET01614 | |
| 0.008 | 0.466 | 0.051 | Dihydroorotase inhibitor | 0.051 0.023 DBMET02460 | DBMET02460 | |
| 0.021 | 0.48 | 0.119 | Exportin-1 inhibitor | 0.082 0.023 DBMET01613 0.119 0.005 DBMET02460 | DBMET02460 | |
| 0.028 | 0.494 | 0.222 | Heat shock protein 90 alpha antagonist | 0.222 0.038 DBMET02460 | DBMET02460 | |
| 0.026 | 0.493 | 0.245 | Arachidonic acid antagonist | 0.245 0.007 DBMET02460 | DBMET02460 | |
| 0.007 | 0.475 | 0.044 | Histamine H2 receptor agonist | 0.044 0.028 DBMET02460 | DBMET02460 | |
| 0.025 | 0.494 | 0.303 | Mannose-6-phosphate isomerase inhibitor | 0.122 0.097 DBMET01613 0.303 0.005 DBMET02460 | DBMET02460 | |
| 0.005 | 0.476 | 0.028 | Caspase 2 inhibitor | 0.028 0.026 DBMET02457 0.027 0.026 DBMET02461 | DBMET02457 | |
| 0.006 | 0.479 | 0.07 | Nav1.7 sodium channel blocker | 0.07 0.043 DBMET01613 0.066 0.049 DBMET02460 | DBMET01613 | |
| 0.003 | 0.478 | 0.018 | CC chemokine 9 receptor antagonist | 0.018 0.01 DBMET02460 | DBMET02460 | |
| 0.016 | 0.492 | 0.05 | CXC chemokine 1 receptor antagonist | 0.05 0.038 DBMET02460 | DBMET02460 | |
| 0.022 | 0.499 | 0.204 | HIV-1 integrase (Overall Integration) inhibitor | 0.13 0.034 DBMET01613 0.204 0.011 DBMET02460 | DBMET02460 | |
| 0.084 | 0.562 | 0.294 | Peptidyltransferase inhibitor | 0.205 0.093 DBMET02455 0.261 0.043 DBMET02466 0.21 0.087 DBMET02457 0.204 0.094 DBMET02459 0.294 0.027 DBMET02461 | DBMET02461 | |
| 0.007 | 0.485 | 0.091 | Selectin antagonist | 0.091 0.031 DBMET02461 | DBMET02461 | |
| 0.022 | 0.501 | 0.112 | Proteasome inhibitor | 0.112 0.072 DBMET02461 | DBMET02461 | |
| 0.094 | 0.573 | 0.495 | 5 Hydroxytryptamine uptake stimulant | 0.377 0.019 DBMET01613 0.495 0.005 DBMET02460 | DBMET02460 | |
| 0.005 | 0.491 | 0.033 | Bradykinin B2 receptor agonist | 0.033 0.016 DBMET02461 | DBMET02461 | |
| 0.011 | 0.498 | 0.066 | Dopamine beta hydroxylase inhibitor | 0.047 0.038 DBMET01613 0.066 0.01 DBMET02460 | DBMET02460 | |
| 0.009 | 0.497 | 0.04 | VCAM-1 antagonist | 0.04 0.026 DBMET02461 | DBMET02461 | |
| 0.009 | 0.497 | 0.04 | VCAM antagonist | 0.04 0.026 DBMET02461 | DBMET02461 | |
| 0.024 | 0.513 | 0.112 | Vanilloid 4 agonist | 0.085 0.033 DBMET01613 0.112 0.01 DBMET02460 | DBMET02460 | |
| 0.02 | 0.511 | 0.083 | Chymotrypsin inhibitor | 0.083 0.051 DBMET02461 | DBMET02461 | |
| 0.005 | 0.497 | 0.062 | TRPA1 antagonist | 0.062 0.04 DBMET02460 | DBMET02460 | |
| 0.007 | 0.499 | 0.033 | Glutamate (mGluR4) agonist | 0.033 0.025 DBMET02460 | DBMET02460 | |
| 0.018 | 0.512 | 0.162 | Alkaline phosphatase inhibitor | 0.162 0.052 DBMET02460 | DBMET02460 | |
| 0.011 | 0.508 | 0.12 | Alcohol dehydrogenase inhibitor | 0.082 0.077 DBMET01614 0.12 0.035 DBMET02460 0.088 0.067 DBMET02461 | DBMET02460 | |
| 0.004 | 0.503 | 0.042 | Inosine monophosphate dehydrogenase inhibitor | 0.042 0.02 DBMET02460 | DBMET02460 | |
| 0.003 | 0.503 | 0.048 | Geranyltranstransferase inhibitor | 0.048 0.024 DBMET02460 | DBMET02460 | |
| 0.006 | 0.513 | 0.05 | Xanthine dehydrogenase inhibitor | 0.05 0.046 DBMET02460 | DBMET02460 | |
| 0.003 | 0.514 | 0.037 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.037 0.013 DBMET02460 | DBMET02460 | |
| 0.036 | 0.548 | 0.238 | Transcription factor STAT3 inhibitor | 0.238 0.093 DBMET02460 0.182 0.161 DBMET02461 | DBMET02460 | |
| 0.003 | 0.52 | 0.038 | Diamine oxidase inhibitor | 0.038 0.026 DBMET01613 0.036 0.029 DBMET02460 | DBMET01613 | |
| 0.012 | 0.531 | 0.054 | Heparanase inhibitor | 0.054 0.035 DBMET02460 | DBMET02460 | |
| 0.003 | 0.523 | 0.048 | Carbonic anhydrase II inhibitor | 0.048 0.046 DBMET02460 | DBMET02460 | |
| 0.002 | 0.525 | 0.021 | Alpha 2c adrenoreceptor agonist | 0.021 0.009 DBMET01613 | DBMET01613 | |
| 0.021 | 0.546 | 0.278 | Triose-phosphate isomerase inhibitor | 0.09 0.06 DBMET01614 0.278 0.005 DBMET02460 | DBMET02460 | |
| 0.003 | 0.528 | 0.049 | Fructose-1,6-bisphosphatase inhibitor | 0.049 0.026 DBMET02460 | DBMET02460 | |
| 0.007 | 0.533 | 0.077 | Carbonic anhydrase V inhibitor | 0.077 0.037 DBMET02460 | DBMET02460 | |
| 0.009 | 0.535 | 0.038 | Hedgehog signaling activator | 0.038 0.005 DBMET02460 | DBMET02460 | |
| 0.032 | 0.56 | 0.182 | Melanin inhibitor | 0.128 0.118 DBMET01614 0.182 0.05 DBMET02460 | DBMET02460 | |
| 0.024 | 0.552 | 0.16 | Cell wall synthesis inhibitor | 0.16 0.057 DBMET02460 0.117 0.104 DBMET02461 | DBMET02460 | |
| 0.004 | 0.532 | 0.035 | Retinoid X alpha receptor agonist | 0.035 0.024 DBMET02460 | DBMET02460 | |
| 0.003 | 0.532 | 0.019 | Retinoid X beta receptor antagonist | 0.019 0.018 DBMET02460 | DBMET02460 | |
| 0.029 | 0.56 | 0.182 | Thiol protease inhibitor | 0.138 0.084 DBMET02460 0.182 0.047 DBMET02461 | DBMET02461 | |
| 0.004 | 0.535 | 0.063 | Complement C3a chemotactic receptor antagonist | 0.063 0.02 DBMET02461 | DBMET02461 | |
| 0.011 | 0.543 | 0.102 | Glutamate (mGluR7) antagonist | 0.102 0.009 DBMET02460 | DBMET02460 | |
| 0.005 | 0.539 | 0.03 | Integrin alpha2beta1 antagonist | 0.03 0.013 DBMET02460 | DBMET02460 | |
| 0.01 | 0.547 | 0.137 | GABA aminotransferase inhibitor | 0.137 0.01 DBMET02460 | DBMET02460 | |
| 0.006 | 0.542 | 0.094 | Na+ K+ transporting ATPase inhibitor | 0.094 0.037 DBMET02460 | DBMET02460 | |
| 0.037 | 0.581 | 0.222 | Hepatoprotectant | 0.139 0.121 DBMET02455 0.17 0.089 DBMET02466 0.138 0.122 DBMET02457 0.139 0.122 DBMET02459 0.222 0.053 DBMET02461 | DBMET02461 | |
| 0.022 | 0.565 | 0.198 | DOPA decarboxylase inhibitor | 0.198 0.007 DBMET02460 | DBMET02460 | |
| 0.014 | 0.558 | 0.091 | Dihydroorotate oxidase inhibitor | 0.091 0.006 DBMET02460 | DBMET02460 | |
| 0.003 | 0.549 | 0.039 | Protein kinase (CK1) epsilon inhibitor | 0.039 0.028 DBMET01613 | DBMET01613 | |
| 0.006 | 0.552 | 0.038 | Glutamate (mGluR3) agonist | 0.038 0.013 DBMET02460 | DBMET02460 | |
| 0.035 | 0.584 | 0.169 | Histone acetyltransferase inhibitor | 0.169 0.114 DBMET02460 | DBMET02460 | |
| 0.038 | 0.59 | 0.282 | Transcription factor STAT inhibitor | 0.282 0.067 DBMET02460 | DBMET02460 | |
| 0.006 | 0.563 | 0.041 | Integrin alpha2 antagonist | 0.034 0.032 DBMET01613 0.041 0.019 DBMET02460 | DBMET02460 | |
| 0.031 | 0.592 | 0.182 | Adenylate kinase inhibitor | 0.102 0.064 DBMET01614 0.182 0.018 DBMET02460 0.129 0.036 DBMET02461 | DBMET02460 | |
| 0.002 | 0.563 | 0.025 | Fructose-1,6-bisphosphatase 1 inhibitor | 0.025 0.014 DBMET02460 | DBMET02460 | |
| 0.011 | 0.572 | 0.058 | Fatty acid synthase inhibitor | 0.058 0.038 DBMET02460 | DBMET02460 | |
| 0.004 | 0.569 | 0.058 | Alpha 1d adrenoreceptor agonist | 0.058 0.012 DBMET01613 0.054 0.014 DBMET02460 | DBMET01613 | |
| 0.039 | 0.605 | 0.372 | Antibacterial | 0.239 0.187 DBMET02465 0.372 0.09 DBMET02466 0.252 0.175 DBMET02460 0.354 0.1 DBMET02461 | DBMET02466 | |
| 0.004 | 0.571 | 0.036 | Protocollagen prolyl hydroxylase inhibitor | 0.036 0.009 DBMET02461 | DBMET02461 | |
| 0.01 | 0.578 | 0.097 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.041 0.03 DBMET01613 0.097 0.003 DBMET02460 | DBMET02460 | |
| 0.008 | 0.579 | 0.063 | HIV-1 integrase inhibitor | 0.063 0.06 DBMET02460 | DBMET02460 | |
| 0.007 | 0.581 | 0.452 | Histidine decarboxylase inhibitor | 0.219 0.011 DBMET02460 0.452 0.003 DBMET02461 | DBMET02461 | |
| 0.02 | 0.596 | 0.061 | Immunoglobulin Fc receptor antagonist | 0.061 0.023 DBMET02460 | DBMET02460 | |
| 0.013 | 0.59 | 0.324 | Ferrochelatase inhibitor | 0.169 0.031 DBMET01613 0.324 0.005 DBMET02460 | DBMET02460 | |
| 0.014 | 0.591 | 0.133 | Uric acid excretion stimulant | 0.133 0.031 DBMET02460 | DBMET02460 | |
| 0.003 | 0.581 | 0.032 | MAP3K8 inhibitor | 0.032 0.014 DBMET02460 | DBMET02460 | |
| 0.01 | 0.592 | 0.083 | Glucose-6-phosphate isomerase inhibitor | 0.083 0.008 DBMET02460 | DBMET02460 | |
| 0.005 | 0.588 | 0.099 | Monophenol monooxygenase inhibitor | 0.099 0.077 DBMET02460 | DBMET02460 | |
| 0.017 | 0.6 | 0.1 | Xanthine oxidase inhibitor | 0.1 0.06 DBMET02460 | DBMET02460 | |
| 0.007 | 0.594 | 0.083 | Potassium channel (Inward rectifier) activator | 0.05 0.035 DBMET01613 0.083 0.007 DBMET02460 | DBMET02460 | |
| 0.007 | 0.593 | 0.134 | Phenylalanine 4-hydroxylase inhibitor | 0.134 0.015 DBMET02460 | DBMET02460 | |
| 0.013 | 0.6 | 0.349 | GABA C receptor agonist | 0.199 0.02 DBMET01613 0.349 0.007 DBMET02460 | DBMET02460 | |
| 0.001 | 0.589 | 0.031 | Alpha 2a adrenoreceptor agonist | 0.031 0.005 DBMET01613 0.022 0.008 DBMET02460 | DBMET01613 | |
| 0.007 | 0.598 | 0.08 | Potassium channel (ATP-sensitive) activator | 0.048 0.034 DBMET01613 0.08 0.007 DBMET02460 | DBMET02460 | |
| 0.009 | 0.603 | 0.054 | Cathepsin B inhibitor | 0.054 0.042 DBMET02461 | DBMET02461 | |
| 0.007 | 0.601 | 0.081 | Carbonic anhydrase VA inhibitor | 0.081 0.036 DBMET02460 | DBMET02460 | |
| 0.006 | 0.605 | 0.054 | Membrane dipeptidase inhibitor | 0.037 0.032 DBMET02460 0.054 0.013 DBMET02461 | DBMET02461 | |
| 0.012 | 0.611 | 0.168 | Microtubule formation inhibitor | 0.168 0.029 DBMET02460 | DBMET02460 | |
| 0.004 | 0.605 | 0.26 | Alcohol oxidase inhibitor | 0.26 0.005 DBMET02460 | DBMET02460 | |
| 0.012 | 0.614 | 0.1 | M18 aspartyl aminopeptidase inhibitor | 0.1 0.091 DBMET02460 | DBMET02460 | |
| 0.01 | 0.613 | 0.065 | Aldosterone antagonist | 0.065 0.016 DBMET02460 | DBMET02460 | |
| 0.005 | 0.61 | 0.018 | Methylmalonyl-CoA mutase inhibitor | 0.018 0.014 DBMET02460 | DBMET02460 | |
| 0.008 | 0.614 | 0.094 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.094 0.018 DBMET02460 | DBMET02460 | |
| 0.001 | 0.608 | 0.012 | Human herpes virus 5 capsid protein P40 inhibitor | 0.012 0.01 DBMET02460 | DBMET02460 | |
| 0.006 | 0.613 | 0.089 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.089 0.017 DBMET02460 | DBMET02460 | |
| 0.014 | 0.623 | 0.342 | Aminopeptidase B inhibitor | 0.148 0.039 DBMET02460 0.342 0.006 DBMET02461 | DBMET02461 | |
| 0.005 | 0.617 | 0.042 | Endothelin-converting enzyme inhibitor | 0.042 0.036 DBMET02461 | DBMET02461 | |
| 0.004 | 0.616 | 0.075 | 3-Oxoacyl-[acyl-carrier-protein] synthase inhibitor | 0.075 0.027 DBMET02460 | DBMET02460 | |
| 0.002 | 0.616 | 0.021 | Protease (Human cytomegalovirus) inhibitor | 0.021 0.018 DBMET02460 | DBMET02460 | |
| 0.047 | 0.662 | 0.413 | Sodium/bile acid cotransporter inhibitor | 0.337 0.049 DBMET02455 0.356 0.036 DBMET02466 0.344 0.044 DBMET02457 0.342 0.045 DBMET02459 0.413 0.014 DBMET02461 | DBMET02461 | |
| 0.009 | 0.626 | 0.078 | Potassium channel (Tandem pore domain) blocker | 0.078 0.038 DBMET02460 | DBMET02460 | |
| 0.002 | 0.619 | 0.062 | Fumarate hydratase inhibitor | 0.062 0.01 DBMET02460 | DBMET02460 | |
| 0.008 | 0.628 | 0.104 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.104 0.009 DBMET02460 | DBMET02460 | |
| 0.002 | 0.623 | 0.041 | Estradiol 17 beta-dehydrogenase inhibitor | 0.041 0.03 DBMET02460 | DBMET02460 | |
| 0.006 | 0.632 | 0.103 | Aconitate hydratase inhibitor | 0.103 0.008 DBMET02460 | DBMET02460 | |
| 0.002 | 0.629 | 0.036 | Nicotinic acid receptor 2 antagonist | 0.036 0.007 DBMET02460 | DBMET02460 | |
| 0.001 | 0.628 | 0.017 | Carbonic anhydrase X inhibitor | 0.017 0.012 DBMET02460 | DBMET02460 | |
| 0.001 | 0.628 | 0.017 | Carbonic anhydrase VIII inhibitor | 0.017 0.012 DBMET02460 | DBMET02460 | |
| 0.004 | 0.634 | 0.114 | Biliverdin reductase inhibitor | 0.114 0.015 DBMET02460 | DBMET02460 | |
| 0.004 | 0.636 | 0.1 | Acyl-CoA dehydrogenase inhibitor | 0.1 0.016 DBMET02460 | DBMET02460 | |
| 0.005 | 0.64 | 0.334 | Glutamate decarboxylase inhibitor | 0.148 0.013 DBMET02460 0.334 0.003 DBMET02461 | DBMET02461 | |
| 0.001 | 0.635 | 0.018 | Ileal bile acid transport inhibitor | 0.018 0.011 DBMET02461 | DBMET02461 | |
| 0.001 | 0.637 | 0.021 | Nicotinic acid receptor 1 antagonist | 0.021 0.008 DBMET02460 | DBMET02460 | |
| 0.021 | 0.657 | 0.295 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.295 0.025 DBMET02460 | DBMET02460 | |
| 0.005 | 0.641 | 0.08 | Inducible nitric-oxide synthase inhibitor | 0.08 0.062 DBMET02460 | DBMET02460 | |
| 0.013 | 0.65 | 0.394 | Alpha-N-acetylglucosaminidase inhibitor | 0.148 0.056 DBMET01613 0.123 0.075 DBMET01614 0.394 0.009 DBMET02460 | DBMET02460 | |
| 0.002 | 0.639 | 0.044 | CXC chemokine 2 receptor antagonist | 0.044 0.007 DBMET02460 | DBMET02460 | |
| 0.002 | 0.641 | 0.038 | Lysine carboxypeptidase inhibitor | 0.038 0.011 DBMET02461 | DBMET02461 | |
| 0.003 | 0.642 | 0.075 | Thymidylate synthase inhibitor | 0.075 0.009 DBMET02461 | DBMET02461 | |
| 0.002 | 0.642 | 0.021 | Antibiotic Anthracycline-like | 0.021 0.009 DBMET02460 | DBMET02460 | |
| 0.002 | 0.643 | 0.057 | Guanylate cyclase inhibitor | 0.057 0.014 DBMET02460 | DBMET02460 | |
| 0.013 | 0.657 | 0.1 | Factor XII inhibitor | 0.082 0.062 DBMET02466 0.1 0.037 DBMET02461 | DBMET02461 | |
| 0.002 | 0.652 | 0.027 | Glutamate (mGluR1a) agonist | 0.027 0.01 DBMET02460 | DBMET02460 | |
| 0.005 | 0.663 | 0.234 | Porphobilinogen synthase inhibitor | 0.234 0.009 DBMET02460 | DBMET02460 | |
| 0.002 | 0.663 | 0.022 | Aminopeptidase P inhibitor | 0.022 0.017 DBMET02461 | DBMET02461 | |
| 0.01 | 0.672 | 0.047 | Cathepsin F inhibitor | 0.047 0.016 DBMET02461 | DBMET02461 | |
| 0.01 | 0.677 | 0.132 | Protease inhibitor | 0.132 0.04 DBMET02461 | DBMET02461 | |
| 0.066 | 0.735 | 0.135 | CC chemokine 6 receptor antagonist | 0.135 0.054 DBMET02460 | DBMET02460 | |
| 0.004 | 0.672 | 0.117 | Argininosuccinate synthase inhibitor | 0.117 0.016 DBMET02460 | DBMET02460 | |
| 0.016 | 0.687 | 0.052 | DNA helicase inhibitor | 0.052 0.045 DBMET02461 | DBMET02461 | |
| 0.012 | 0.685 | 0.058 | Topoisomerase II beta inhibitor | 0.058 0.023 DBMET02460 | DBMET02460 | |
| 0.002 | 0.678 | 0.11 | Ornithine carbamoyltransferase inhibitor | 0.058 0.033 DBMET02460 0.11 0.014 DBMET02461 | DBMET02461 | |
| 0.003 | 0.683 | 0.156 | Phosphofructokinase-1 inhibitor | 0.156 0.017 DBMET02460 | DBMET02460 | |
| 0.012 | 0.695 | 0.098 | Keratolytic | 0.098 0.032 DBMET02460 | DBMET02460 | |
| 0.012 | 0.699 | 0.167 | Cathepsin H inhibitor | 0.167 0.036 DBMET02460 | DBMET02460 | |
| 0.002 | 0.69 | 0.036 | Purinergic P2Y15 antagonist | 0.036 0.01 DBMET02460 | DBMET02460 | |
| 0.007 | 0.702 | 0.183 | Mucolytic | 0.128 0.047 DBMET02460 0.183 0.018 DBMET02461 | DBMET02461 | |
| 0.006 | 0.708 | 0.162 | Aminopeptidase I inhibitor | 0.099 0.028 DBMET02460 0.162 0.011 DBMET02461 | DBMET02461 | |
| 0.007 | 0.711 | 0.07 | Potassium channel Kv1.1 blocker | 0.07 0.006 DBMET02460 | DBMET02460 | |
| 0 | 0.704 | 0.012 | Glutamate (mGluR6) agonist | 0.012 0.009 DBMET02460 | DBMET02460 | |
| 0.011 | 0.716 | 0.181 | Glutamate dehydrogenase inhibitor | 0.135 0.019 DBMET02460 0.181 0.012 DBMET02461 | DBMET02461 | |
| 0.001 | 0.708 | 0.019 | Telomerase stimulant | 0.019 0.009 DBMET02460 | DBMET02460 | |
| 0.018 | 0.725 | 0.075 | Transcription factor RelA inhibitor | 0.075 0.022 DBMET02460 | DBMET02460 | |
| 0.009 | 0.719 | 0.058 | Human rhinovirus A protease inhibitor | 0.058 0.036 DBMET02460 0.057 0.036 DBMET02461 | DBMET02460 | |
| 0.011 | 0.729 | 0.116 | Purinergic P2X1 antagonist | 0.116 0.012 DBMET02460 | DBMET02460 | |
| 0.005 | 0.724 | 0.157 | Expectorant | 0.1 0.069 DBMET02460 0.157 0.033 DBMET02461 | DBMET02461 | |
| 0.006 | 0.731 | 0.057 | Glutamate (mGluR8) agonist | 0.057 0.008 DBMET02460 0.036 0.031 DBMET02461 | DBMET02460 | |
| 0 | 0.728 | 0.023 | Aminopeptidase A inhibitor | 0.023 0.009 DBMET02461 | DBMET02461 | |
| 0.002 | 0.742 | 0.028 | Vanilloid 2 agonist | 0.028 0.012 DBMET02460 | DBMET02460 | |
| 0.006 | 0.749 | 0.132 | CYP2A6 inhibitor | 0.132 0.022 DBMET02460 | DBMET02460 | |
| 0.007 | 0.755 | 0.086 | Ornithine decarboxylase inhibitor | 0.086 0.061 DBMET02460 0.081 0.066 DBMET02461 | DBMET02460 | |
| 0.002 | 0.763 | 0.054 | Antimetabolite | 0.054 0.029 DBMET02461 | DBMET02461 | |
| 0.022 | 0.79 | 0.096 | Transcription factor NF kappa B stimulant | 0.096 0.043 DBMET02461 | DBMET02461 | |
| 0.005 | 0.781 | 0.028 | Complement factor 1s inhibitor | 0.028 0.011 DBMET02460 | DBMET02460 | |
| 0.001 | 0.79 | 0.089 | Ribonucleotide reductase inhibitor | 0.089 0.024 DBMET02461 | DBMET02461 | |
| 0.001 | 0.79 | 0.089 | Ribonucleoside-diphosphate reductase inhibitor | 0.089 0.022 DBMET02461 | DBMET02461 | |
| 0.004 | 0.794 | 0.043 | Carbonic anhydrase I stimulant | 0.043 0.021 DBMET02461 | DBMET02461 | |
| 0.005 | 0.803 | 0.065 | Botulinum neurotoxin type A inhibitor | 0.065 0.031 DBMET02460 0.052 0.051 DBMET02461 | DBMET02460 | |
| 0.012 | 0.826 | 0.055 | Carbonic anhydrase II stimulant | 0.055 0.03 DBMET02461 | DBMET02461 | |
| 0.004 | 0.821 | 0.06 | Carbonic anhydrase stimulant | 0.06 0.04 DBMET02461 | DBMET02461 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |